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CHLORPROMAZINE INDUCED TRACE METAL ALTERATIONS
CHAPTER I 
INTRODUCTION
In 1901 Sir William Osier (23) said: "One of the first duties
of the physician is to educate the masses not to take medicine."
Never before has a society been exposed to such an extraordinary 
array of drugs which alter mood or perception. This has occurred at a 
time when the indiscriminate use of pharmacologic agents is the norm 
rather than aberration (226).
There is little doubt that drugs old and new, have reduced mor­
bidity and mortality rates and continue to do so. It is disconcerting, 
however, to find that improper medication, polypharmacy, and adverse drug 
reactions are to the point where drugs, either because of their reac­
tions, or economic impact on the family unit, constitute what is approach­
ing a national health problem (219). In scxne reported series, adverse 
reactions occurred in 14 per cent of the hospitalized patients and 7 per 
cent of those reactions were fatal or life threatening (325). In 5 per 
cent of admissions to a general hospital, drug reactions were a major 
factor leading to hospitalization (325).
In an attempt to decelerate this trend, the Food and Drug Admin­
istration has been given "new teeth." But at this writing "package stuff­
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ing" and legislation have not worked, and it is not implausible that the 
independent physician will likely continue to prescribe as he has done 
before in defiance of those edicts (248).
Only the most recalcitrant psychoanalyst would hold that disa­
bling symptoms of anxiety should not be treated with medical as well as 
psychological measures. On the other hand, few responsible physicians 
would rely solely on drug therapy. Too much evidence indicates that 
anxiety may result from unresolved intrapsychic conflicts or environmen­
tal stresses to ignore these as etiological factors. To the extent that 
conflicts may be resolved or the environment improved, anxiety may be re­
lieved in part or whole. Drug therapy, therefore, is most logically con­
sidered as adjunctive rather than primary in the management of anxiety 
reactions, psychophysiological disorders, or simply the nervousness of 
everyday life. Too much reliance on drugs for ameliorating symptoms may 
deprive patients of other types of treatment, perhaps resulting in more 
harm than benefit (l7l).
Various derivatives of phenothiazine, differing in the nature 
of the substituents in the 2- and 10- positions on the tricyclic struc­
ture, are in common clinical use as antipsychotic agents. These compounds 
have received wide acceptance despite a high incidence of side effects, 
including pseudoparkinsonism, neuroendocrine abnormalities and hepatic 
dysfunction. The author has examined chlorpromazine administration, 




In the past decade at least 50 million patients have received 
chlorpromazine and more than 10,000 publications have dealt with its ac­
tions (17, 137). Chlorpromazine and related phenothiazines derivatives 
are employed primarily in two situations: treatment of psychiatric pat­
ients and treatment of nausea and vomiting (l37).
Historical Aspects
In 1951 research workers at Rhone Poulenc - Specie Research 
Laboratories in France discovered the diverse properties of chlorpromazine 
(thorazine) while searching for new drugs that would have a profound ef­
fect on the central nervous system (l7, 137, 334).
The phenothiazine nucleus was already well known; phenothiazine 
had been used as an anthelminthic for livestock, a urinary antiseptic for 
man and was antihistaminic. Early animal studies of chlorpromazine, how­
ever, demonstrated that this derivative had more far-reaching and provoc­
ative effects on the central and autonomic nervous systems, the cardio­
vascular system and the skeletal-muscular system. The drug prevented 
apomorphine-induced vomiting; blocked conditioned response to stimuli; 
potentiated and prolonged the action of narcotics, sedatives and anes­
thetics; caused muscular flaccidity and helped to produce hypothermia.
3
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It was clear that with a compound that possessed such a diversity of 
pharmacological properties, the scope of its possible clinical applica­
tions was extremely wide (334). According to Smith, Kline and French 
Laboratories (SKF) (334), Laborit and collaborators introduced the use 
of chlorpromazine in anesthesia and developed its use as an anesthetic 
potentiator and in producing the state of "artificial hibernation." This 
state was produced when the "lytic cocktail," (a combination of chlor­
promazine, meperidine hydrochloride and promethazine hydrochloride) was 
administered in combination with external cooling to surgical patients, 
resulting in hypothermia, slowed metabolism and reduced oxygen require­
ments. The author reasoned that the patient in this state of physical 
and mental suspension would be more resistant to the stress of surgical 
trauma.
Further investigations showed that this hypothermic anesthesia 
also helped patients to resist psychic stress, and according to SK&F (334) 
two European psychiatrists. Delay and Deniken, demonstrated that chlor­
promazine alone was effective in the treatment of psychiatric disorders 
(14).
Chlorpromazine proved to have an antipsychotic effect - it would 
dispel delusions and hallucinations. Secondly, it calmed hyperactive and 
agitated patients without clouding consciousness or dulling mental facul­
ties (this is because phenothiazine derivatives do not block nerve im­
pulses traveling upward to the cortex). Although at high dosages the 
drug would produce a sedative effect and even sleep (the result of inhi­
bition of the reticular activating system), patients were easily aroused 
and, in the absence of their psychotic manifestations, were rational and
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cooperative (334).
Further studies in the United States confirmed the clinical val­
ue of the drug and, in 1954, SKF released Thorazine (chlorpromazine,
SK&F) as a tranquilizer, antipsychotic, potentiator and antiemetic (334).
Chemistrv
Phenothiazine has a three-ringed structure in which two benzene 
rings are linked by a sulfur and a nitrogen (Table l). Usual substitu­
tions are at positions 2 and 10. The addition of a substituent at posi­
tion 2 increases the potency of phenothiazines for depressing motor ac­
tivity and conditioned avoidance responses in animals and for altering 
psychotic behavior in humans. A CFg substitution in this position great­
ly increases antipsychotic and antiemetic potency as well as the tendency 
to produce extrapyramidal signs (137).
The nature of the substituent at position 10 also influences 
pharmacological activity (Table l). The phenothiazines can be divided 
into three groups on the basis of substitution at this site. The group 
with an aliphatic side chain includes chlorpromazine, promazine, triflu- 
promazine, and methoxypromazine. This is the least potent group of the 
phenothiazines, as can be seen by the dosage range. The next group, of 
approximately the same or somewhat lower order of clinical potency, con­
tains a piperidine moiety in the side chain and includes mepazine and 
thioridazine. The most potent antipsychotic compounds in terms of effec­
tive dose levels are those with a piperazine (or piperazinyl) group, such 
as fluphenazine, perphenazine, trifluoperazine, etc. These have markedly 
augmented antiemetic properties and a greater tendency to produce park­
insonism, but diminished sedative effects; they are also the most active
TABLE 1











































in suppressing conditioned avoidance responses in animals (l37).
All the phenothiazines used in psychiatry have a three-carbon 
bridge between the ring and side chain nitrogen atoms. This is in con­
trast to anticholinergic phenothiazines used in the treatment of parkin­
sonism (e.g., ethopropazide, diethazine) and to antihistaminic phenothia­
zines (promethazines, pyrathiazine), which have only two carbons sepa­
rating the nitrogens. One exception should be noted: methdilazine,
which produces sedation but lacks significant antipsychotic actions, has 
three carbons between the nitrogens (137).
In spite of their distinctive pharmacological and psychological 
effects, Sainsbury (307) maintains that the therapeutic efficacy of 
phenothiazines does not relate consistently to their chemical structure. 
According to him, the chemical structural features of the phenothiazines 
thus far have not provided for a sufficiently constant association be­
tween pharmacological, psychological and clinical effects to develop a 
theory of their mode of action.
Psvchopharmacoloov and Effect on the Nervous Svstem
The phenothiazines are almost unique in the variety of the 
pharmacological responses which they evoke (277). Chlorpromazine, for 
example, has activities, depending on dose, ranging from antibacterial 
and possibly antitumor activity to antihistaminic and tranquilizing prop­
erties.
A review of the variability seen in drug responses has been 
published by Irwin (l88). He concluded that the art of predicition and 
treatment may be enhanced by due attention to at least three factors:
(l) the baseline level, (2) the arousal-provoking quality of the environ-
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ment, and (3) to the condition of behavioral arousal of the subject as 
important indicators of his response to drugs. The response to a drug 
is a complex drug - tissue - personality - environment interaction.
According to Summerfield (35l) the most important central ef­
fect of chlorpromazine is its singular sedative effect. Animals become 
quiet and sleepy, remain in unnatural positions (so-called catalepsy), 
and at higher doses fall asleep. However, they are always readily awak­
ened. Aggressive animals like rhesus monkeys and fighting fish become 
calm. Anxious animals like rabbits lose their fear.
The site and mechanism of action of chlorpromazine has been the 
object of many investigations, but no definitive decisions can be reached 
(l39, 301). Some experiments suggested an action on the reticular ac­
tivating system, but the consensus is that a tranquilizing action can 
occur at dose levels and in species in which the drug does not depress 
this system (l39).
In the brain, chlorpromazine is said to influence the hypothal­
amus and the limbic system. The reticular apparatus of the brain stem 
is depressed with small doses of chlorpromazine; large doses cause a 
stimulation of the reticular formation. This stimulation results in the 
appearance of extrapyramidal symptoms, resembling the tremors of parkin­
sonism in man. Chlorpromazine also inhibits the "arousal reaction," a 
response of the electrical activity of the brain, recorded in the elec­
troencephalogram (334, 59).
Chlorpromazine is a potent local anesthetic. It blocks epineph­
rine and is a potent serotonin antagonist. Chlorpromazine is a potent 
antiemetic, and a weak antihistaminic and ganglionic blocking agent. It
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has anticonvulsant properties against nicotine and nikethamide convul­
sions, but not against strychnine or electroshock. Chlorpromazine has 
some antipyretic properties; it reduces blood pressure. Respiration is 
increased with small doses of chlorpromazine; with higher doses there is 
some depression. Vasomotor centers of the brain are depressed by chlor­
promazine, and it potentiates the action of narcotics and analgetics at 
doses which are not in themselves hyponotic or analgetic. High concen­
trations of chlorpromazine decrease the conductivity of isolated nerve 
fibers (334, 17, 137, 139).
Disturbances of the central nervous system may be due in part 
to a deficiency of nutrient substances (294). This deficiency may be 
due to a diminished utilization of food by the brain or by an enhanced 
requirement of energy in consequence of stress phenomena. Furthermore, 
it has been known for many years that a marked reduction in blood sugar, 
reduced oxygen pressure in the air, or diminished cerebral blood flow 
can produce psychotic symptoms. In addition, it is known that a latent 
psychosis can be activated by sleep deprivation or by certain central 
stimulants.
In mice 1-5 mg/kg of chlorpromazine orally or subcutaneously 
produced a reduction in spontaneous motor activity proportional to the 
dose (65). Activity in mice was reduced about 50 per cent for the first 
hour after a dose of 2 mg/kg subcutaneously, and completely suppressed 
at 5 mg/kg. Even at the latter dose, however, the mice showed no ataxia 
or prostration and responded readily to stimuli with coordinated activ­
ity. This behavior is in marked contrast to the effects of barbiturates, 
which caused reduction in spontaneous motor activity only at doses wriiich
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produced ataxia or hypnosis. Some of the chlorpromazine effect was still 
evident 5 hours after small doses and it was partially antagonized by 
large doses of pipradrol (l09).
Investigators have speculated whether chlorpromazine, by reduc­
ing motivational strength, would eliminate sterotyped behavior caused by 
pretrial submersion of rats swimming in a water T-maze. However, chlor­
promazine produced severe behavioral disorganization and decreased learn­
ing and retention of both sterotyped and nonsterotyped responses. The 
results suggested that chlorpromazine may affect sensory input and ef­
fective integration of sensory data rather than motor incoordination or
motivational strength (245).
In a study of the effect of reserpine, chlorpromazine, and 
meprobamate on learning in the newborn, the drugs were given to gravid 
rats and the offspring were measured for learning activity. Only the 
offspring of the meprobamate-treated mothers required significantly more 
trials to reach a control level of learning (368, 256).
The sexual behavior of male rats under the influence of chlor­
promazine has been reported by Zimbardo and Barry (382) and by Gillett 
(l28). A reduction in rate of copulation, the number of copulations and
the latency period was observed, but there was a wide range of indivi­
dual variation.
Chlorpromazine has the unusual ability to suppress responses to 
auditory or visual conditioned stimuli in doses which do not markedly 
alter responses to unconditioned stimuli. In rats conditioned to climb 
a pole at the sound of a bell, pretreatment with 2 mg/kg of chlorproma­
zine subcutaneously blocked response to the bell in about 40 per cent of
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the trials (65, 6, 13, 112). Chlorpromazine doses of 10 mg/kg blocked 
the conditioned response in about 85 per cent of the rats, although the 
animals were capable of responding to an unconditioned stimulus— namely 
an electric shock to feet (65, 6, 10, 112). In a similar situation,
0.5 mg/kg of chlorpromazine reduced the response of rats to an auditory 
stimulus and higher doses abolished the response, without loss of muscu­
lar coordination (70).
Grossman and Miller (l49) reported the evaluation of alcohol 
and chlorpromazine as fear-reducing drugs. A variable-length "telescope 
alley" apparatus was used, and the procedure involved approach training 
and avoidance training with and without drugs. Two testing conditions 
were measured, i.e., fear and fear-plus-pain (electroshock). Hungry 
rats tested under alcohol ran reliably faster and farther toward food 
than did controls in both fear and fear-plus-pain tests. Chlorpromazine- 
treated rats consistently ran farther and faster than controls in fear- 
plus-pain tests but slower than did controls in fear only test (l9).
Davis et jd. (SO) studied the acquisition of a fear-motivated 
response to chlorpromazine. In their procedure training was sequential 
so that drug effects on the conditioning process could be analyzed. 
Chlorpromazine inhibited establii''' ,nt of an association between condi­
tioned stimulus and internal fear-motivated behavior and its drive and 
cue function. The data indicated that chlorpromazine might prevent pro­
gressive extension of psychoneurotic symptoms. Chlorpromazine also pro­
moted persistent extinction of fear-conditioned response (271).
Irwin (l87) showed that tolerance development to chlorpromazine 
was considerably accelerated by increasing the intensity of the condi-
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tioned (buzzer) or the unconditioned (shock) stimulus in rats.
The effect of drugs on conditioning and habituation to arousal 
stimuli in animals was studied by Key and Bradley (203). Chlorpromazine 
increased threshold for both conditioned (behavior) and unconditioned 
(EEC) arousal response to auditory stimuli in cats and eventually blocked 
arousal response completely.
Pigeons trained to respond to a red light with a fixed ratio 
response (rewards given after a given number of pecks) and a blue light 
with a fixed interval response (reward after 5 minutes), still differen­
tiated between the colored lights after 1.7 or 3 mg/kg of chlorpromazine
i.m. (92). There was no interference with fixed rate performance, but 
long pauses developed during fixed interval periods.
In a study of tenporal discrimination, pigeons were trained to 
peck a lighted key and were presented with the key alternately dark and 
lighted. The key was dark for interval of 3-30 seconds. Pecking of the 
lighted key was reinforced only after the shortest or, in a second ex­
periment, longest interval that the key was dark. The pigeons were able 
to estimate the duration of dark interval. Chlorpromazine attentuated 
discrimination of duration of a stimulus but did not abolish pecking 
(299).
Thompson (354) studied the effects of chlorpromazine on "aggres­
sive" responding in rats trained in lever pressing on a regular water- 
reinforcement schedule. The results showed that chlorpromazine-treated 
animals made fewer responses both before and after onset of extinction 
but exhibited relatively greater acceleration in rate of responding im­
mediately after onset of extinction as compared with saline control group.
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In schizophrenic patients and in monkeys with implanted corti­
cal and subcortical electrodes, chlorpromazine produced a record resem­
bling that of drowsiness and light sleep (250). Essig and Carter (lOS) 
have reported that chronic administration of high doses of chlorproma­
zine (44-77 mg/kg i.m.) produced major convulsions and behavior sugges­
tive of hallucinations in monkeys (Macaca mulatta).
Eiectroencephalographic studies in normal human subjects, after 
intravenous or intramuscular administration of chlorpromazine, have shown 
patterns associated with fatigue, drowsiness, or sleep, depending on the 
doses used (95, 135). In patients given chlorpromazine, the changes in­
duced by intravenous hexobarbital were intensified and occurred sooner 
(135). In epileptic patients with normal resting EEGs showed an activa­
tion of paroxysmal discharge while those with abnormal resting EEGs 
showed intensification of abnormal patterns (l07).
Endocrine and Metabolic Effects of Chlorpromazine
Many of the chemical changes influenced by the administration 
of phenothiazines have been postulated as being responsible for tran­
quilizing actions, including depletion of epinephrine and its precursors, 
increased oxidation of epinephrine, chelation of epinephrine, combina­
tion with indole, and competitive inhibition of indoles (5).
Rats given single subcutaneous or oral doses of chlorpromazine 
from 10-50 mg/kg usually showed little change or a slight decrease in 
oxygen consumption, which appeared to be in proportion to the decrease 
in body temperature (36, 70). After administration of 20 mg/kg/day, this 
metabolic effect had disappeared. No antagonism to the metabolic effects 
of thyroxine was found (36).
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In human subjects, basal metabolic rate changed little after 
chlorpromazine doses up to 2 mg/kg (95, 94, 350). Similarly, cerebral 
oxygen consumption was not changed by chlorpromazine in intravenous or 
intramuscular doses of 50-300 mg, unless the blood pressure dropped con­
siderably (252).
Chlorpromazine (30 mg i.v.) increased serotonin in the spleen, 
decreased serotonin in the heart, and had little effect on serotonin in 
the visceral tissues of rabbits previously given 5-hydroxytrytophan-3-Cl^ 
(lO Jig i.v.); LSD and BOL (brcanolysergic acid diethylamine) (500 |ig i.v.) 
increased serotonin levels in heart and BOL decreased them. Chlorproma­
zine and BOL decreased serotonin in all parts of brain (310).
In a study of drug induced alterations in the subcellular dis­
tribution of 5-hydroxytryptamine in rat's brain, Schanberg and Giarman 
(315) reported that CNS depressants (chlorpromazine, reserpine, phéno­
barbital, and methylparafynol) significantly increased the proportion of 
free 5-HT, regardless of whether they increased, decreased or had no ef­
fect on total 5-HT. LSD-25, imipramine, and p-phenylisopropylhydrazine
increased the total 5-HT, accounted for by greater increase in bound 
than in free 5-HT.
The effect of drugs on amino acid levels in rat brain was stud­
ied by DeRopp and Snedeker (88). Convulsive agents and CNS stimulants, 
including amphetamine, significantly increased free alanine in brain. 
Chlorpromazine and methoxypromazine significantly increased brain gluta­
mine and alanine. The authors concluded that there is correlation be­
tween the rise in brain alanine and convulsant or excitant activity.
Chlorpromazine (20 mg/kg i.p.), simultaneously with or 17 hours
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after iproniazid, inhibited or reversed the effects of iproniazid on 
catecholamines and serotonin in rat brain. The authors concluded that 
the effects of chlorpromazine may either be due to a hypothermic or a 
direct-specific effect (42, 10, 237).
Chlorpromazine consistently increased epinephrine content of 
various areas of dog brain, whereas small doses increased and higher 
doses decreased norepinephrine levels (234, 89, 142).
Chlorpromazine was found by Burton and Salvador (44) to be bound 
to nicotinamide-methlpherase in vivo in mice, and in vitro. In the pres­
ence of this drug, enzyme activity was increased but the affinity of sub­
strate (nicotinamide) was reduced. Competitive inhibition between chlor­
promazine and nicotinamide may also be a factor. The relationship be­
tween the drug-enzyme complex and psychophysiology was speculated on.
Van Peenen and Way (362) noted that 3 mg/kg of chlorpromazine, 
given one hour earlier, blocked normal adrenaline-produced adrenal ascor- 
bate depletion but not that of histamine or aspirin. Gold et ad. (l30) 
in a study on 20 psychiatric patients reported that the normal two-fold 
rise in urinary 17-ketogenic steroids following intravenous administra­
tion of mepyrapone was impaired by chlorpromazine (lOO to 200 mg daily).
Holzbauer and Vogt (l76) reported no effect of chlorpromazine 
on ACTH secretion in rats. Nasmyth (260) found that 2.5 mg/kg chlor­
promazine in the rat did not, itself, stimulate ACTH release and failed 
to prevent ascorbate depletion after adrenaline, surgical stress, or 
high doses of histamine.
Egdahl and co-workers (lOO, 101) reported that 3.5 mg/kg of 
chlorpromazine in the dog produced significant adrenal response as meas-
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sured by 17-OHCS levels in adrenal venous blood after i.v. administra­
tion of the drug. Saski (312), in guinea pigs, and Harwood and Mason 
(154) in monkeys, found increases in circulating adrenal steroids fol­
lowing chlorpromazine administration. Sapieka (Sll) reported that 50, 
150, and 300 mg/kg of chlorpromazine in the rat in single oral doses in­
creased ACTH release as measured by ascorbate depletion.
Smith et al, (338) and Buckley et (41) suggest that other 
investigators who found blockade of the stress-response following chlor­
promazine administration may have been examining the system only after 
the pituitary ACTH stores had been exhausted.
Polishuk and Fligelman (284) reported that amenorrhea was found 
in six women out of eleven treated with chlorpromazine (150-200 mg i.v.) 
and in all four women treated with higher doses (350-400 mg i.v.). This 
amenorrhea was found to be of the low estrone, normal follicle stimu­
lating hormone (FSH) type for the first group, but marked increases in 
FSH were reported for the higher dose group.
Chlorpromazine has been shown to increase blood glucose levels 
and to counteract insulin hypoglycemia in animals (l94, 305) yet, it has 
also been noted that chlorprwnazine causes a mild hypoglycemia and does 
not prevent the hypoglycemia produced by adrenaline in the rabbit (37).
Charatan and Bartlett (56) reported that chlorpromazine caused 
abnormal glucose tolerance curves in schizophrenic patients. Amdisen (7) 
performed glucose tolerance tests on a group of patients during long-term 
treatment with chlorpromazine. Very few patients showed glycosuria or 
abnormally high fasting blood sugar levels. However, glucose tolerance 
tests of the diabetic type were found in 40 per cent of the patients on
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chlorpromazine.
Human subjects given 25-50 mg of chlorpromazine intramuscularly 
or 1.5 mg/kg intravenously showed a slight tendency to increased blood 
sugar one hour later (95). No change was noted in the response to in­
travenous insulin of patients pretreated with chlorpromazine (216), and 
no change in the hyperglycemic response to surgical stress was observed 
(16).
Insulin potentiates the hypothermia and prolonged the hexobar­
bital sleeping time normally caused by chlorpromazine; chlorpromazine 
does not potentiate the hypoglycemic effects of insulin (222).
Significant weight gain is commonly observed among patients 
taking phenothiazine (62). Physical inactivity and a high-calorie diet 
were considered the most likely contributing causes for the weight gain 
during hospitalization (l38).
Chlorpromazine has been shown to produce uncoupling of oxida­
tive phosphorylation in various preparations of liver and brain (27, 8l). 
Like dinitrophenol, chlorpromazine also inhibits adenosinetriphosphatase 
activity (228, 85).
In mitochondria from the brains and livers of rats, chlorproma­
zine and imipramine both strongly inhibited oxygen uptake and phosphoryl­
ation, but on a molar basis chlorpromazine was twice as active as imipra­
mine. The uncoupling effect was not very marked. No marked specificity 
for brain versus liver mitochondria was observed. The inhibitory effects 
were independent of the substrate (227, l).
Oxygen uptake by slices of brain cortex showed no change during 
the first 0.5 hour after the addition of 20-251 ml/l of chlorpromazine.
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remained steady for the next 0.5 hour and then decreased in proportion 
to the concentration of chlorpromazine (274).
Chlorpromazine reduced phospholipid turnover in brain according 
to Ansell and Dohmen (S) but Magee and Rossiter (233) and Grossi et al. 
(148) reported an increase for low levels of the drug.
Iriye and Simmonds (186) found that the effect of chlorpromazine 
on the phosphorylase level of rat brain differs according to the mode of 
sacrifice. When control rats are sacrificed by immersion in liquid ni­
trogen, the level of brain phosphorylase is lower than when the rats are 
sacrificed by inhalation of chloroform. Chlorpromazine depresses the 
phosphorylase level of rats immersed in liquid nitrogen but enhances the 
enzymatic activity of brains of rats sacrificed with chloroform. The 
enhancing effect produced by chloroform on the enzyme level as well as 
the further enhancing effect of a pretreatment with chlorpromazine are 
not peculiar to chloroform, since the same effects can be reproduced by 
nitrogen gas asphyxia.
According to Masurat et al.. (239) chlorpromazine in concentra­
tions from 8.5 X 10“̂  M to 6.8 x 10”  ̂M, either greatly activated or in­
hibited hexokinase activity, determined by measuring spectrophotometri- 
cally the reduction of TPN (triphosphopyridine nucleotide). The biphasic 
action of chlorpromazine was a function of the relative concentration of 
drug and Mg-ATP substrate. The author indicated that chlorpromazine may 
function as metabolic regulator, primarily by interfering with utiliza­
tion of ATP.
Burton and Salvador (44) studied the effect of chlorpromazine, 
nicotinamide, and nicotinic acid on pyridine nucleotide levels of human
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blood. Nicotinic acid (0.5-0.8 g/day p.o.) increased blood pyridine 
nucleotide four- to six-fold in human subjects, whereas nicotinamide 
(O.5-1.1 g/day p.o.) did not. Chlorpromazine (50 mg/day p.o.) did not 
alter nicotinic acid-induced increase in blood pyridine nucleotide lev­
els.
Glende and Cortnatzer (l29) found that chlorpromazine and other 
phenothiazines inhibited the uptake of into the sulfolipids.
Chlorpromazine significantly inhibited various types of mito- 
chondial swelling in rat brain and liver preparations. The effects were 
noted at concentrations as low as 10"^ M for brain using triton as the 
swelling agent, or at 10"^ M for liver with thyrazine as the swelling 
agent. The authors stated that the concentrations of chlorpromazine were 
less than those necessary to produce changes in enzyme activities or ox­
idative phosphorylation; thus, chlorpromazine changes membrane permea­
bility (341, 342, 335).
The effect of some phenothiazine derivative on the hemolysis of 
red blood cells in vitro was studied by Freeman and Spirtes (l24). The 
compounds studied in human and dog erythrocytes were chlorpromazine, 
chlorpromazine sulfoxide, promazine, and promethazine. Chlorpromazine 
caused the greatest increase in hemolysis time; prochlorperazine was ef­
fective at the lowest concentration. The data suggest that phenothia­
zines decrease permeability of erythrocytes to water by altering cell 
membrane structure.
Chlorpromazine (5 or 40 mg/kg s.c.) produced a 13-19 per cent 
increase in survival time of leukemic mice. However, doses of 17 or 33 
mg/kg had no effect (210).
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It has been suggested that chlorpromazine alters the permeabil­
ity of various membranes to substances like norepinephrine and serotonin, 
and the antipsychotic activity of chlorpromazine has been attributed to 
its membrane effects (l90, 151, 384).
Serum alkaline phosphatase was determined at the start and dur­
ing the course of treatment of patients with 350 mg chlorpromazine per 
day. During the first three weeks of treatment a significant elevation 
in enzyme activity was obtained in 2/3 of the subjects, which exceeded 
the upper limit of normal at times. In no instance was jaundice present. 
The elevation in enzyme activity spontaneously regressed in face of con­
tinuing treatment with the drug (l65).
On the other hand. Caverns (54) in a similar study found that 
at 1-3 hours after parenteral administration of 0.025 mg chlorpromazine 
and of 0.100 mg orally the alkaline phosphatase activity decreased in the 
men and women. In ten mental patients viiio were treated for 1-10 months 
with 300 mg chlorpromazine daily no appreciable variation of the alkaline 
phosphatase occurred.
However, several other investigators (380, 46, 177, 241) in 
studying the activity of alkaline phosphatase in blood plasma, serum, or 
blood during treatment of schizophrenia with chlorpromazine found no 
change in alkaline phosphatase activity.
Kusch and Heinvich (21l) reported, after a single dose of 5 mg 
of chlorpromazine/lOO g body weight in rats, a marked increase in alka­
line phosphatase in the liver within 18 hours. This increase was accom­
panied by a decrease of alkaline phosphatase in the plasma.
Dasgupta and Mukherjee (75) reported that chlorpromazine de-
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presses the alkaline phosphatase activity of both cytoplasm and the nu­
cleus of the brain cells, particularly those known to be normally rich 
in ribonucleic acid.
The effect of 10 compounds with psychotomimetic or tranquil- 
izing activity on alkaline phosphatase and lactic and malic dehydrogenase 
activities of brain preparations was studied. Chlorpromazine signifi­
cantly increased alkaline phosphatase. Malic and lactic dehydrogenase 
was relatively resistant to the compounds tested (63).
Phosphatase activity in the rat brain, measured at pH 7.2-7.5 
with P-nitrophenol phosphate as a substrate, was markedly increased by 
chlorpromazine jji vitro and ^  vivo. The results from the comparative 
in vitro studies with chlorpromazine and a detergent, Sterox, indicated 
that the increase by chlorpromazine was not due to its ability to solu- 
blize proteins from the membranes of subcellular structures, but prob­
ably due to its ability to reveal active sites of phosphatase which are 
normally masked under normal conditions (9l).
Injection of chlorpromazine produced a 6-7-fold increase in the 
activity of the acid phosphatase inhibited by L-tartrate (type III), 
even after castration. There was no causal relation between serum phos­
phatase (type II) and weight changes of the prostate (212).
Ashby et al» (il) reported that chlorpromazine caused an in­
crease in CNS carbonic anhydrase in the 3 parts of the CNS studied. 
Chlorpromazine caused large increases in the carbonic anhydrase concen­
tration of the kidneys.
The influence of chlorpromazine on liver arginase was studied.
A clear inhibitory action could be shown in the in vitro experiments up
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to a concentration of 1 x 10"^ M, but no decrease of liver arginase ac­
tivity was found in the jji vivo experiments after 89 to 93 days of treat­
ment (206).
Chlorpromazine has been reported to produce a decrease in aconi- 
tase in kidney particle preparations due to complexing of the drug and 
enzyme (276). In an interesting study, Khouw et al. (204) reported 
that chlorpromazine increases blood levels of alcohol by inhibition of 
the conversion of ethanol to acetaldehyde.
In rat brain homogenates chlorpromazine decreased the cytochrome 
C content, but only at high concentrations. A subcutaneous dose of 
50 mg cpz/kg body weight only weakly affected the cytochrome C in the 
brain (l26).
When fresh frozen sections from the brains of Sprague-Dawley 
rats were incubated in a medium containing 0.001-1 mM chlorpromazine or 
trifluoperazine, the cytochrome C oxidase of various areas of this tis­
sue was inhibited. The histochemical technique employed permitted the 
degree of inhibition of cytochrome C oxidase to be related to the tissue 
concentration of the drug rather than to the concentration of drug in the 
incubating medium (25l). However, when large doses of phenothiazines 
(150-200 mg/kg) were administered intraperitoneally to rats, no signifi­
cant inhibition of cytochrome C oxidase was observed. The tissue con­
centration of the drug jji vivo was less than the jjn vitro tissue concen­
tration required to produce a minimum inhibition of cytochrome C oxidase. 
Brain tissue evidently was able to concentrate phenothiazines 100-150- 
fold (251).
Yamamoto et al. (377) reported that chlorpromazine inhibited
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the activity of cytochrome c and oxygen uptake 55.8 per cent at concen­
trations of 5 X 10”^ M; but the S and N - oxides of chlorpromazine showed 
no effect on the activity, even in concentration of 2.5 x 10"^ M.
Inhibitory effect of chlorpromazine on cytochrome oxidase of 
rat liver mitochondria or rat brain homogenate was investigated (376, 82, 
83, 84). The inhibitory effect of chlorpromazine on cytochrome oxidase 
was reversed by dialysis of chlorpromazine with enzyme preparations; de­
creased by Fe Clg, and not affected by glutathione. Chlorpromazine in­
hibited catalose, but not homogentisic case or ascorbic acid oxidase 
(376).
Chlorpromazine was reported to inhibit D-amino acid oxidase as 
a result of competition with flavin adenine dinucleotide (372, 373, 374, 
375, 223, 227).
Chlorpromazine and other phenothiazine derivatives were found 
to inhibit the succinoxidase activity most strongly. In all cases, cyto­
chrome oxidase was more sensitive and succinic dehydrogenase less sensi­
tive to inhibition than was the complete succinoxidase system. Brain 
succinoxidase was less sensitive to inhibition than was liver succinoxi­
dase (337, 159).
Johannesson and Lausen (l9l) studied the jji vitro effect of 
chlorpromazine on brain cholinesterase. They found that chlorpromazine 
at 100 |ig/g inhibited cholinesterase activity in brain tissue from an in­
fant. The authors concluded that excitation seen as side effect of chlor­
promazine (parodoxical action) is due to its inhibition of cholinesterase.
Chlorpromazine and its sulfoxide inhibited the cholinesterases 
of human plasma and red cells. The former drug was more active than the
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latter and the plasma enzyme was more sensitive than that of the red 
cells. The inhibition was competitive in type (l04).
Cholinesterase activity of 8 rats was determined following in­
jections of 15 mg chlorpromazine per kg of body weight. The slight in­
crease was not significant statistically (74).
Aminazine, (Russian name for chlorpromazine) 1 - 2  mg/kg, in­
creases the level of cholinesterase activity in the blood of the animals. 
This level of the cholinesterase activity in the blood of the animals 
varies from individual to individual, remaining, however, the same in 
each animal. The changes in enzyme activity proceeds in phases. The 
dogs used for this experiment had permanently implanted electrodes in 
the rostal region of the reticular formation (l50).
Chlorpromazine in a concentration below 10“  ̂M significantly in­
hibited the esterase activity of human blood plasma on acetylcholine and 
succinylcholine (327).
Chlorpromazine had no effect upon lactic dehydrogenase isolated 
from anaerobic yeast cultures (238). However, Chagovets and Lakhnol (55) 
reported that lactic, glutamic and citric dehydrogenase activity in cer­
ebral cortex, cerebellum and skeletal muscles studied was greatly de­
pressed (70-75% decrease).
Valdiguie et al. (359) reported that treatment with 600 mg 
chlorpromazine showed maximum serum lactic dehydrogenase value of 1207 
units. These values occurred at 18 hours.
Some authors reported an increase in serum GOT and GPT after 
chlorpromazine treatment (275, 213).
Cats were given aminazine, 5 or 10 mg/kg wt. intramuscularly.
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and killed 1 hour later. The activities of glutamic dehydrogenase and 
cytochrome oxidase in the homogenates of intervertébral ganglia and that 
of cytochrome oxidase in Gaulle and Burdach's nuclei were increased. On 
the other hand, succinate dehydrogenase and cytochrome oxidase activities 
were decreased in ventrolateral thalamic nuclei and the activities of 
all 3 enzymes in the motor area of the cerebral cortex. Similar but more 
pronounced effects were found in isolated mitochondria (98).
Results of experiments with rabbits and rats showed that the 
level of citric acid in blood serum of rabbits was relatively constant 
and did not change following injection of aminazine. Some rise in the 
citric acid content of serum occurred in rats which received toxic doses 
of aminazine and may have been caused by ensuing hypothermia (268).
Gielen (l27) reported that intraperitoneal injections of 5 mg 
chlorpromazine increased serum ornithine carbamyl transferase, lactic 
dehydrogenase, oxyloacetic-glutamic transaminase, malic dehydrogenase 
and isocitric dehydrogenase within 12 hours after administration to rats, 
while serum pyruvic-glutamic transaminase and 1,6-diphosphofructoaldolase 
and hepatic lactic dehydrogenase showed no significant changes. Subcu­
taneous injections of chlorpromazine (0.5 mg 3 times/week for 8 weeks) 
increased the level of hepatic isoenzyme lactic dehydrogenase (fraction 
5) during the 5th to 7th week of administration, although hepatic and 
serum lactic dehydrogenase and serum oxalacetic-glutamic transaminase, 
malic dehydrogenase, and ornithine carbamyl transferase were unchanged 
(127).
Serum total proteins were unchanged in patients undergoing 
chlorpromazine therapy; serum globulin tended to be increased and albumin
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decreased (236, 257). Electrophoretic study of serum proteins in nine 
patients showed a double p-globulin peak in all of them. Such a "beta 
split" has been reported in various states involving tissue damage (in­
fectious disease, acute rheumatism); its significance in relation to 
chlorpromazine is uncertain (355).
Nakajima (259) reported that the inactivation of serotonin by 
ceruloplasmin is not accelerated by lysergic acid diethlamide-25 (LSD), 
is accelerated by iproniazid, and is accelerated by chlorpromazine and 
EDTA but not to completion. The author concludes that iproniazid acts 
specifically on the serotonin-ceruloplasmin complex, and that chlorpro­
mazine is a nonspecific inhibitor. From the action of EDTA, inactiva­
tion of serotonin depends primarily on protein portion of ceruloplasmin, 
whereas for inactivation of adrenaline by ceruloplasmin, Cu"^ is most 
important (259).
A study was made of the effects of large doses of chlorpromazine 
and levomepromazine on the in vitro formation of noradrenolutin and nor- 
adrenochrome in the serum of seven mental patients. Variation in copper 
concentration in the seven sera was also determined. Before administra­
tion of the drugs the blood copper level was high; there was active pro­
duction of noradrenolutin and a low rate of noradrenochrome product. 
Following drug administration, there was a decrease in blood copper level 
as well as noradrenolutin production whereas the noradrenochrome level 
increased. These results corresponded with clinical improvement of the 
patients (317).
Chlorpromazine at a concentration as high as 1 x 10"^ had no 
inhibitory effect on human ceruloplasmin activity in vitro (7l).
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Nunez (265) investigated the plasma copper level of 50 mental 
patients (27 women, 23 men, ages 14-73 years). After the administration 
of 0.025 g chlorpromazine intramuscularly to the male patients, and
0.050 g orally to the female patients, the value was determined in the 
men 1 hour, and in the women 1.5 hours later. In nearly all patients 
the copper level in the plasma decreased. In manic depressive patients 
it increased.
The copper concentration of the blood plasma was determined in 
25 psychiatric patients before treatment with chlorpromazine and after
1, 3, and sometimes 5 and 7 weeks of treatment. In the majority there 
was a gradual rise in copper concentrations; in twelve patients defi­
nitely abnormal concentrations (above 160 mg/lOO ml) were reached; five 
of these showed extrapyramidal signs. Similar determination in twenty- 
five patients without chlorpromazine showed no rise in copper concentra­
tions (l6).
Daily intramuscular injections of two tranquilizers (chlorpro­
mazine or perphenazine) in guinea pigs caused increases in the copper in 
the caudate nuclei and cerebellar cortex in the absence of administered 
copper. Liver copper was also increased (l68).
Chlorpromazine, 50 mg daily per orally, inhibited the diurnal 
variation in serum iron, but the inhibitory effect was not so evident in 
serum copper (353).
Chlorpromazine, 2 mg/kg intramuscularly, to thirty-six children 
caused some drop of basal blood iron and a lowering of gastro-intestinal 
absorption (iron gluconate administration). The curve after iron sac- 
charate intravenous administration was higher if chlorpromazine was also
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associated. The author ascribes the above action of chlorpromazine to a 
metabolic torpor of the main deposit organs, because of the macrobiotic 
action of the drug (340).
Effect on Body Temperature 
Chlorpromazine lowers body temperature in various laboratory an­
imals, the extent of the change depending on room temperature and chlor­
promazine dose. This hypothermic action was initially attributed to in­
hibition of central thermoregulation, with resulting increased heat loss, 
and muscular relaxation, with decreased heat production. Later specula­
tion involved effects on catecholamines (l92). In mice kept at 25*C,
2 mg/kg of chlorpromazine subcutaneously produced an average minimum tem­
perature of 32.8'C, 5 mg/kg a minimum of 31.9*0, and 10 mg/kg a minimum 
of 30.2*0 (70). With the higher doses, temperatures remained below nor­
mal for over 24 hours. The hypothermic effect in dogs was less marked.
In another study in mice, the average maximum decrease in body 
temperature after 1 mg/kg was 3*0; after 3 mg/kg it was 5.7*0 (208). 
iVhen the high dose of 50 mg/kg was given intraperitoneally to mice kept 
at a room temperature of 27*0, body temperature fell to a low of 23.1*0 
within an hour and then gradually rose to normal (86). The same dose 
given to mice kept at 3*0 reduced body temperature to an average of 
11.7*0 in 1.5 hours (86). With doses of 20 or 30 mg/kg, body tempera­
ture depended on ambient temperature, increasing slightly in a warm room 
and falling to 17.6*0 after 6 hours exposure to 10*0. After single doses 
of chlorpromazine, body temperature effects in rats were about the same 
as those in mice, again depending on room temperature (86).
Fenters and Jeter (llO) reported on the effect of variation in
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body temperature on antibody production in rabbits and mice. Chlorproma­
zine, 5 mg/kg i.m. at 12-hour intervals or intra-abdominally, alone or 
with refrigeration, depressed body temperature of control rabbits and 
those immunized with bovine serum albumin or mice immunized with Diplo- 
coccus pneumoniae vaccine. Pyrogen treatment increased temperature. 
However, alterations in body temperature had no effect on antibody pro­
duction in immunized animals.
Human subjects given ordinary doses of chlorpromazine show in­
consistent temperature effects. When lightly anesthesized patients were 
given 50 mg intravenously and 100 mg intramuscularly, reinforced by doses 
of 50 mg intramuscularly every hour or two, body temperature was main­
tained at 92-94*F for long periods (299).
The antagonistic effect of cold acclimatization on chlorproma­
zine hypothermia is reported to be associated with increased sensitiza­
tion of tissues to adrenaline and noradrenaline (218, 219, 220, 221).
The acute toxicity of chlorpromazine in mice has been found to be eight­
een times higher at a room temperature of 4*C than at 30’C (72). This 
may be due to vasodilatation and associated phenomena.
It is becoming more and more apparent that many of the pre­
viously reported effects of chlorpromazine jji vivo were the result of 
hypothermia rather than a direct effect of the drug. For example, the 
increased incorporation of labeled amino acids into tissues, and the in­
creased concentrations of NAD and nicotinamide which have been observed 
in chlorpromazine-treated animals are related to hypothermia (328), as 
is also the prevention by chlorpromazine of iproniazid acceleration of 
serotonin accumulation in the brain (l8).
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Fortunately, animals which have received chlorpromazine can be 
maintained in an isothermic condition if they are kept in an environment 
of elevated temperature, and most jji vivo work is now done with animals 
so maintained.
Effects on Activitv of Other Drugs
The duration of hypnosis after hexobarbital was more than dou­
bled by 5 mg/kg of chlorpromazine (i.p.), but no alteration in the rate 
of metabolism of the barbiturate or its concentration in brain tissue 
could be demonstrated (39). When chlorpromazine was given subcutaneously 
a 0.5 hour before intravenous hexobarbital, a combination of 30 mg/kg of 
barbiturate and 15 mg/kg of chlorpromazine had an effect equivalent to 
150 mg of hexobarbital alone in rats (70). Similar potentiation has al­
so been observed in guinea pigs and dogs, as well as rabbits (306).
Other investigators have reported potentiation of hexobarbital hypnosis 
in mice (l2, 112) and rats (346).
The potentiating effect of chlorpromazine appears to extend to 
all sedative barbiturates, as well as ethinamate (231). In mice, doses 
of 2.5-5 mg/kg of chlorpromazine prolonged sleeping time after pentobar­
bital (208). In rats, doses of 10-50 mg/kg were effective in combination 
with thiopental, pentobarbital, and amobarbital, and 100 mg/kg of chlor­
promazine moderately prolonged secobarbital sleeping time (334, 161).
Childs et al. (58) found that pretreatment with chlorpromazine 
decreases the induction time of barbital anesthesia without increasing 
the rate of brain penetration. The data suggested that reduced induc­
tion time does not necessarily imply increased permeability of the blood- 
brain barrier; it may have resulted from increased sensitivity of brain
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cells to barbital or hypothermia produced by these drugs.
On the other hand, Kato and Chiesara (l98) reported an increase 
of pentobarbital metabolism induced in rats by chlorpromazine and other 
drugs, with a decrease in sleeping time.
The subcutaneous administration of chlorpromazine in mice, rats, 
and guinea pigs shortened the time of onset of ether anesthesia, and its 
duration was considerably increased at doses of 1.25-20 mg/kg (70). The 
incidence of anesthesia in rats exposed to 80 per cent nitrous oxide was 
increased by chlorpromazine at 20 mg/kg. In rats exposed to 70 per cent 
nitrous oxide the incidence of anesthesia was increased by 50 mg/kg of 
chlorpromazine (s.c.) (50).
Chlorpromazine in doses of 0.25-10 mg/kg (s.c.) eliminated the 
excitement stage and significantly prolonged the hypnotic effect of in­
traperitoneal or oral alcohol in rats (70). A similar effect was seen 
in mice, although the rate of alcohol metabolism was not affected (39). 
The toxicity of alcohol in mice was slightly but significantly increased 
by doses of 0.5 mg/kg of chlorpromazine.
In mice pretreated with chlorpromazine there was a marked in­
crease in the analgesic effects of morphine, meperidine, aspirin, sali- 
cylamide, and phenacetin (70). The rate of tolerance development to 
morphine was not retarded by chlorpromazine in rats (240). On the other 
hand. Carter and David (51) report that chlorpromazine in rats signifi­
cantly decreased the rate of tolerance development to narcotic analgetics 
and hastened recovery during withdrawal.
The duration of action of the maximally effective dose of mor­
phine, 10 mg/kg was markedly prolonged by 10 mg/kg of chlorpromazine
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(319). On the other hand, a different group reported that minimally ef­
fective morphine dose 1.5 mg/kg plus chlorpromazine at 10 mg/kg gave a 
lower incidence of analgesia than chlorpromazine alone (208).
The centrally acting phenothiazines like chlorpromazine were 
found by Fink and Swinyard (ll2) to decrease amphetamine toxicity. The 
weight reducing properties of phenmetrazine were reported to be antago­
nized by chlorpromazine (297).
A study was done in rats by Stein and Seifter (344) to support 
the theory that drugs which are effective against agitation inhibit, 
whereas those effective in depression enhance, reward (self stimulation) 
activity. Imipramine, 5-15 mg/kg, augmented and prolonged d-methamphet- 
amine-induced self stimulation; in contrast, chlorpromazine antagonized 
both methamphetamine-induced self stimulation and also the augmenting ef­
fect of imipramine on the same stimulation. The authors concluded that 
imipramine has a sensitizing effect on the central adrenergic synapses.
Chlorpromazine has been found by Elder and Dille (l02) to an­
tagonize the behavioral effects of LSD, although it inhibits the metabo­
lism of it (l4). Ray and Marrazzi (296) have studied quantitative rela­
tionships of LSD and chlorpromazine effects. LSD-25, in doses 0.19 mg/kg 
small enough to be devoid of gross effect, increased response latency in 
rats to a tone indicating the availability of water reward. This effect 
was greatly reduced by chlorpromazine in doses 0.30 mg/kg, that per se 
did not affect performance. On the other hand, larger but nondepressant 
doses (l mg/kg i.p.) of chlorpromazine increased rather than reduced 
LSD-25 inhibition, whereas still larger doses produced depression of ap­
proach behavior.
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Doses of LSD sufficient to dilate pupils, but producing no other 
physiological effect, 25 ng, could be recognized by human subjects (253). 
Recognition of the threshold dose could be blocked by 25 mg/kg of chlor­
promazine or 10 mg/kg of phenoxybenzamine if given 30 minutes before the 
LSD (255).
The effects of chlorpromazine and lysergic acid diethylamide on 
the arousal response were reported by Key (201, 202). Chlorpromazine,
5 mg/kg or 10 mg/kg, increased the intensity of stimulation necessary to 
elicit arousal response in cats with permanently implanted electrodes. 
After LSD, 10-15 pg/kg i.p., presentation of an auditory stimulus was 
followed by abrupt arousal and long-lasting periods of alerting.
Chlorpromazine antagonized the EEC alerting produced by cholin­
ergic agents, especially eserine salicylate and acetycholine in rabbits 
(346). Cholinesterase inhibitors potentiated the behavioral effects of 
chlorpromazine (l32).
A study of the interaction of nicotinamide with chlorpromazine 
in the mouse showed that nicotinamide alone reduced spontaneous motor 
activity in mice, whereas chlorpromazine, 10 mg/kg, reduced, and chlor­
promazine plus nicotinamide completely inhibited, activity. Nicotinamide 
alone had little effect on pentobarbital anesthesia but did potentiate 
the effect of chlorpromazine and reserpine on pentobarbital anesthesia 
(45).
Chlorpromazine was reported not to enhance the renal toxicity 
of edathamil sodium (a chelating agent, ethylenediamine-tetracetic acid 
calcium disodium salt) in rats (4).
Histamine catabolism during treatment with chlorpromazine was
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studied by Johannesson et al. (l9l). Chlorpromazine, 600 and 750 mg, 
did not affect catabolism of labeled histamine in two psychiatric pat­
ients. These doses were twice those required for therapeutic improve­
ment.
Levin (224) reported that cyanide intoxication is antagonized 
by chlorpromazine in rodents. The protective effect is thought to be 
due to the hypothermia induced.
Metabolism
Many thousands of chronic mental patients successfully rehabil­
itated by phenothiazine drugs, usually have to take these drugs for many 
years or even for life to maintain their remission. Long term toxicity 
studies and knowledge of the normal and abnormal metabolic pathways of 
drug metabolism are mandatory.
The metabolic fate of chlorpromazine is a difficult problem be­
cause various reports have suggested that more than 20 metabolites are 
formed, and there is the further complication that the bile is as impor­
tant a channel of excretion as the urine. Numerous papers have been pub­
lished on the metabolism of chlorpromazine, but relatively few of these 
will be quoted here.
Chlorpromazine is absorbed in 5 to 10 minutes after parenteral 
administration, and in 30 to 60 minutes after it is taken by mouth. Its 
immediate sedative action occurs within this period, to a noticeably 
greater extent with intramuscular than with oral administration. A hy­
pothetical gastrointestinal blood brain barrier, which may prevent ade­
quate absorption, is held responsible for this discrepancy (l7).
The principal routes of chlorpromazine metabolism are sulfoxi-
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dation, déméthylation, N-oxidation, hydroxylation and conjugation (see 
Figure 1) (144, 122).
The oxidation of the heterocyclic sulphur was first reported by 
Salzman and Brodie (308) who found chlorpromazine 5-oxide as a urinary 
metabolite of the drug in man and the dog.
The use of S^^-chlorpromazine has shown that in rats 40-50 per 
cent of single doses (12 mg/kg) are excreted in the urine and an equiva­
lent amount in the feces, the excretion of radioactivity being complete 
in 72 hours (l03). About half of the urinary radioactivity is made up 
of four compounds, the main one (l2 per cent of the dose) being unchanged 
chlorpromazine. The other three were the sulphoxides of chlorpromazine 
and its mono-demethylated and di-demethylated derivatives. The amount 
of these compounds excreted in the urine by rats after a single dose of 
chlorpromazine were 12.3, 5.0, 5.2, and 2.3 per cent, respectively ( 103). 
It has been claimed that man excretes six sulphoxides after chlorproma­
zine and three of these are the sulphoxides of chlorpromazine, and its 
mono-demethylated and di-methylated derivatives (l34).
The proposed mechanism for sulfoxide formation is depicted in 
Figure 2. Haynes (l56) has reported that 5.5 to 7 per cent of chlorpro­
mazine is eliminated as free and bound chlorpromazine by patients re­
ceiving low daily doses (200 mg) of the drug. At higher levels of dos­
age (boo mg) somewhat greater amounts (7 to 9 per cent) are eliminated 
in these forms. Fishman and Goldenberg (ll3) have obtained evidence for 
the presence of at least six sulfoxide derivatives of chlorpromazine in 
the urine of patients receiving the drug.
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Fig, 2. Proposed mechanism for sulfoxide formation
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dimethylchiopromazine and the aromatic hydroxylation and conjugation of 
chlorpromazine were reported (ll5, 304, 378),
The demethylated and hydroxylated compounds are more active in 
animals than the sulfoxide which has a weak sedative action in man. The 
hydroxylated metabolites are conjugated with glucuronic acid and to a 
lesser extent with sulfate (l44).
The formation of the N-oxide of chlorpromazine has now been 
proved and the compound has been isolated from human and dog urine (lis). 
This substance is excreted by humans in amounts equivalent to 0.7 per 
cent of the dose. In dogs the excretion of this metabolite is greater 
than in man, amounting to 2.0 to 3.5 per cent of the dose. On keeping 
this N-oxide for several weeks, it decomposes to give formaldehyde and 
desmonomethyl chlorpromazine. It is interesting to note that the N-oxide 
and its decomposition product, the desmonomethyl derivative are nearly 
as active pharmacologically as the parent drug (287).
There are several publications which suggest that the major 
urinary metabolites in man are polar and water soluble. Four of these 
metabolites have been claimed to be glucuronides of hydroxylated pheno­
thiazine (225, 31). On analogy with phenothiazine itself hydroxylation 
could be expected to occur in positions 3 or 7 or both, but hydroxyla­
tion in other free positions, 1, 4, 6, 8 and 9, cannot be excluded.
Since hydroxylation could be combined with sulfoxidation and demethyla­
tion, a relatively large number of glucuronides are possible. Four of 
these glucuronides have now been identified in dog and human urine, and 
since the aglycones of these glucuronides also occur in the free state 
in the urine, this means that eight more metabolites of chlorpromazine
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have been identified (ll4, 31) (Fig, 3). All of these compounds are de­
rivatives of 7-hydroxychlorpromazine, and include the 5-oxide, the des­
monomethyl and desdimethyl 7-hydroxychlorpromazine and their glucuro­
nides. Fishman and Goldenberg (ll4) have stated that additional hydroxy 
derivatives occur in dog urine and still more in human urine. In fact, 
hydroxylation and glucuronide formation is a more important pathway of 
biotransformation in man than in dog. Whether or not these hydroxy me­
tabolites have pharmacological activity is an open question (l23).
Forrest and Green (l44) stated that just on the basis of the 
above metabolic pathways, over 150 metabolites are possible.
In addition, some unusual but minor urinary metabolites have 
been described, such as 2-chlorphenothiazine and its sulfoxide (l93). A 
chlorpromazine polymer with a hypothesized 1-2 linkage has been attri­
buted to exposure to ultraviolet light and might be related to some 
photosensitivity reactions (l79).
The metabolic pattern varies considerably among patients, so it 
has been tempting to relate patterns of metabolite excretion to clinical 
response. However, evidence for such a relationship is still tenuous.
The rate of relapse of fifteen schizophrenics who were switched to pla­
cebo after chronic treatment with 600 mg daily doses, chlorpromazine was 
not related to the duration of excretion of glucuronide metabolites as 
the same investigators had previously thought (214).
Still, the marked variation in relapse times and the prolonged 
excretion of metabolites following discontinuation of treatment suggests 
that many patients maintain effective tissue levels of drug for consider­
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Fig. 3. Sane chlorpromazine metabolites
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Blood levels of drug have been difficult to measure and even 
more difficult to interpret. Plasma concentrations of chlorpromazine in 
patients chronically treated with 600 to 1200 mg daily doses usually 
range between 1 and 4 mg/ml, with small increases two to three hours 
after individual doses. Following an intramuscular dose of 100 mg, peak 
blood concentrations are attained in 30 minutes, and the drug has virtu­
ally disappeared from the blood after four hours (l80, 214). Blood con­
centrations apparently bear little relationship to clinical pharmacologic 
effects.
A complete post-mortem analysis of drug distribution was done 
on a patient, who received daily oral doses of 900 mg of chlorpromazine 
up to death. The concentration of drug in various parts of the brain 
varied from 1.6 to 9.6 mg/gm wet tissue, as compared with concentration 
in hair of 124 mg/gm, lung 97.5 mg/gm, and liver 13.5 mg/gm (l2l).
Adverse and Side Effects
Definitions
Sir George Pickering (278) pointed out that the uncritical use 
of terms not only tends to make them meaningless but, what is worse, it 
also makes scientific communication difficult and imprecise.
Although they are to be found elsewhere, it will be helpful in 
this endeavor to bring together definitions of toxic effect, adverse ef­
fect, side effect, and drug allergy.
"Adverse effect" has broad and far reaching implications in 
that, as well as toxic effects as defined below, it also includes non- 
pharmacological consequences of drug use: e.g., the population explosion
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in India resulting from effective antimicrobial therapy and the geriat­
ric problem vriiich we now have as a result of advances in drug therapy.
The "toxic effects" of a drug are the consequences of its phar­
macologic actions, by whatever mechanism and for whatever reason, oc­
curring promptly or after a latent period, directly or indirectly, as a 
result of one or more effects on tissue or functional activity by the 
drug. A toxic effect is a pharmacologic function, which has become un­
desirable and is a threat to normal physiologic function, if not a threat 
to life. Usually by being excessive, toxic effects may be attributed to 
the pharmacologic effects of a drug which also provide its therapeutic 
usefulness. Or, they may be associated with other facets of the pharma­
cologic properties of the drug. And, of course, toxic effects result 
from drugs which have no therapeutic value - industrial chemicals, chem­
icals which are used only for destructive purposes, and agents which are 
not intended for man or animal and affect them only by accident (247, 
264).
The "allergic drug reaction" is an immunologic reaction to drugs 
which can only develop in subjects in whom the specific antibody is al­
ready present, usually as a result of previous exposure to the drug.
The basic pharmacologic effect, in all the allergic reaction, is the for­
mation of antigen from drug. Theoretically, therefore, an allergic drug 
reaction cannot occur the first time a subject receives a drug, whereas 
the toxic reaction can (247, 264).
A "side effect" is a pharmacologic effect other than the one 
sought for in the particular use of the drug. Thus, a side effect need 
not be adverse, non-therapeutic, or even unpleasant, or it may be a fatal
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effect. Often a pharmacologic action leads to a side effect in one con­
text and a therapeutic effect in another. Dryness of the mouth is a 
side effect of atropine when it is used to reduce intestinal mobility, 
while reduction of intestinal motility is a side effect of atropine when 
it is used by the anesthesiologist to dry the secretions of the mouth 
and respiratory tract. Thus, an effect of a drug becomes a side effect 
not because it is bad or unpleasant or because of what it does, but only 
because it is not the pharmacologic action on which the therapy is based 
(247, 249, 264).
According to Modell (247), "drug idiosyncrasy" has been defined 
by Rosenheim as uncharacteristic pharmacologic reactions in particular 
patients: e.g., excitement after barbiturate.
"Drug intolerance" is characterized by the production of typical 
pharmacologic effects by unusually small doses of drug (247).
"Drug-induced disease" implies a response to drug in which a 
disease results from its use, it does not imply any kind of pharmacologic 
effect. It is proposed to designate as drug-induced diseases only those 
consequences of the use of drugs which are characterized by functional 
disturbances which persist after the offending drug has been withdrawn 
and has been grossly eliminated (247).
Chlororomazine-Induced Diseases
The administration of chlorpromazine leads to jaundice in 1-5 
per cent of the recipients (257, 384, 90, 99, 302). This phenomenon has 
been considered a manifestation of individual host idiosyncrasy or hyper­
sensitivity to the drug (90, 99). Accordingly the likelihood has been 
considered that the adverse effect chlorpromazine may have upon the liver
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is aggravated by the coincidence of hypersensitivity. Some support for 
this view is provided by the demonstration that almost 50 per cent of 
patients who receive chlorpromazine develop some hepatic dysfunction 
(16, 93, 90).
Popper (286) stated that drugs which produce cholestatic jaun­
dice in some persons cause a subicteric injury to the bile secretory ap­
paratus of the liver cells in all persons. It is proposed that a super­
imposed hypersensitivity reaction to the same drug leading to nonspecific 
drug hepatitis results in the development of the commonly seen cholesta­
tic drug hepatitis with jaundice. Nonspecific drug hepatitis and the 
hepatic reaction resembling viral hepatitis both possibly represent im­
munologic injuries. The difference between these two reactions may only 
be quantitative, and they should be considered as variants of the same 
group. Such an explanation might account for occasional transitional 
stages.
The most prominent and frequent of the neurological disorders 
complicating the use of the major tranquilizing drugs has been the dys­
kinesias which have mimicked the naturally occurring extrapyramidal dis­
eases.
It has been known for several years that extrapyramidal disor­
ders occur frequently in patients taking phenothiazines; however, a re­
duction in dosage or cessation of medication appeared to produce a return 
to the normal state (l6). Hunter et (iBS) recently suggested that 
such extrapyramidal side effects are not always reversible. They found 
13 of 250 chronically ill female patients in a mental hospital to have an 
irreversible syndrome of dyskinesias affecting the face and head. None
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of the 200 men in the same hospital were affected.
The incidence of drug-induced parkinsonism varies with the drug, 
the dose, the duration of treatment and the age and sex of the patients. 
Ayd (15) found in an extensive survey that parkinsonism occurred in 15.4 
per cent of 3,775 patients but mild akiesia was not recorded. On the 
other hand, clinicians who feel that the development of an extrapyramidal 
syndrome is necessary and look for very mild changes find an incidence 
of 90 per cent or more. In several small series of patients specifically 
examined for signs extrapyramidal reactions the incidence has been 100 
per cent (332). Women seem to be more frequently affected than males.
To some extent this may reflect the use of larger dosages in women, but 
hormonal factors may well play a role and the administration of an estro­
genic agent has been reported to precipitate parkinsonism in patients on 
phenothiazines therapy (l4l). Although no age specific-rates are avail­
able, older patients are generally considered more apt than younger ones 
to develop extrapyramidal reactions. Ayd (l5) stressed the similarity 
in age distribution of a large number of cases of drug-induced parkin­
sonism and the mean age of onset of Parkinson's disease. In any event 
the Parkinson syndrome resembling parkinsonism including the character­
istic hand posture has been described in two infants born of a schizo­
phrenic mother receiving large doses of phenothiazines derivatives (l64).
In these circumstances, it is clear that the question of pre­
disposition to the development of extrapyramidal reactions is extremely 
complex. Myriathopoulous and Kurland (258) suggested that hereditary 
factors may play a role but their statistical evidence is not fully con­
vincing. Other authors, although noting marked individual differences
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up to fifteen-fold in the dosage required to induce parkinsonism, were 
unable to relate the occurrence thereof or the dosage required to family 
history of parkinsonism (155).
Hollister and Glazener (l73) found that eight of thirty-six pa­
tients with Parkinson's disease admitted to a mental hospital had con­
current schizophrenia and described one patient whose neurological dis­
ease developed during chronic treatment with a phenothiazine drug.
There have been several post-mortem reports of structural al­
teration of the basal ganglia in patients who had been on large doses of 
phenothiazine drugs (303, 289).
Ocular Reactions and Hyperpigmentation
The occurrence of ocular lesions following chlorpromazine in­
gestion was probably first noted by Bock (28) in 1962 who described 
changes in the lens in three patients who were on long-term chlorproma­
zine therapy. In two of these patients, the lens changes were of the 
typical senile variety and were of no significance. In the third pa­
tient the lens changes were described as "fine powdery white spots on 
the anterior surface of the central pupillary area."
Mackiewicz and Greshon (229) have demonstrated cerebellar le­
sions in guinea pigs treated with long-term oral doses of chlorpromazine. 
They believe these alterations are irreversible.
Greiner and Berry (l46) described corneal and lens opacities as 
well as abnormal skin pigmentation in a group of seventy patients, all 
women, viho had been receiving doses of chlorpromazine averaging 500 to 
1,500 mg daily for three years or longer prior to the first evidence of 
the side effects. Of seventy patients described, twenty-one had very
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marked bluish-gray pigmentation of the skin on exposed areas of the face, 
neck, and hands. Of the later group of twenty-one patients, twelve had 
grossly visible opacities affecting the cornea and lens.
Santanove (313) reports dermatological studies on seventy-eight 
patients receiving abnormally high doses of chlorpromazine and related 
phenothiazines derivatives for prolonged periods. These patients de­
veloped pigmentary changes in the exposed areas of the skin after expo­
sure to specific bands of light. Histochemical studies suggested that 
this color was melanin or a melanin-like substance. The phototoxic ac­
tion of sunlight acting on abnormal amounts of the phenothiazines in the 
skin produced an inflammatory response followed by increased production 
of melanin. The accumulation of melanin, or melanin plus chlorpromazine 
or its metabolites is thought to cause the purple color. The skin win­
dow technique demonstrated a sequence of inflammatory cells which trans­
port the pigment to the blood stream. It is postulated that the cellu­
lar transportation of the pigment from the skin into the blood stream 
may produce the generalized melanosis found on autopsy.
Identical findings were reported by others and have come to be 
known as the "skin-eye syndrome" (20, 380, 108, 159, 319, 47).
Bolt and Forrest (33) reported that ij2 vitro and in vivo stud­
ies strongly suggest a causual relationship between chlorpromazine in­
duced hyperpigmentation of the skin and the drug metabolite 7-hydroxy- 
chlorpromazine rather than with chlorpromazine itself.
Most investigators have reported no significant reduction of 
visual acuity associated with lens or corneal opacities, but there have 
been a few exceptions (47, 369, 230, 329). There have also been sporadic
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reports of partial resolution of eye lesions when chlorpromazine is with­
drawn or partially replaced by other drugs (l20).
Scott and Nading (324), in experiments with frogs have observed 
that several phenothiazine drugs including chlorpromazine effect the re­
lease of melanin-stimulating hormone from the hypophysis.
Of the many drugs currently used, the phenothiazines have been 
implicated in agranulocytosis with greatest frequency. According to the 
registry on drug induced blood dyscrasis of the American Medical Associa­
tion, through June 1965 (347) chlorpromazine was implicated 83 times, 
promazine 30 times and mepazine 13 times as the only drug given to pa- 
tients who developed agranulocytosis.
Agranulocytosis due to phenothiazines occurs most frequently in 
older people. In the compilation by the A.M.A. Committee on Drug Reac­
tions (347), 70 per cent of the patients were women and 30 per cent were 
men. This peculiar sex distribution may not be significant since it has 
been estimated that 70 per cent of phenothiazines have been prescribed 
for women (26l), thereby increasing the risk of reaction. The higher 
incidence of drug sensitivity in older age groups suggests greater sus­
ceptibility with age.
The blood cell count during phenothiazine induced agranulocyto­
sis shows marked leukopenia with complete absence of neutrophils and 
monocytes. Lymphopenia is present as well. Early in the disease the 
bone marrow appears aplastic. It consists primarily of fat and contains 
no cells other than occasional nuclei, resembling lymphocytes. Anemia 
does not generally occur, despite the aplastic appearance of the marrow 
because the red cell survival time is 120 days. As long as recovery or
49
death occurs within a relatively short time, anemia never really gets 
the opportunity to develop (280).
If the drug is discontinued, and infection is avoided, the pa­
tient will recover within about two weeks. As recovery begins, the ab­
solute lymphocyte count increases and if followed within 24 hours by a 
secondary decline, as the neutrophils suddenly increase in number (281).
The concept that a biochemical host defect could be responsible 
for chlorpromazine induced agranulocytosis has a precedent. For example, 
hemolytic anemia occurs whenever primaquine is given to a patient whose 
red cells are deficient in glucose-6-phosphate dehydrogenase (87).
Hollister (l75, 174) concluded that the occurrence of agranulo­
cytosis requires two elements which must be brought together, a drug 
capable of inducing a toxic reaction, and a patient vAo reacts abnormally 
and hence is unable to compensate for the compound's toxic effect. This 
may result from either an inability to detoxify or eliminate the com­
pound so that it accumulates or remains in active form, or a limited 
function of a cellular system which is overcome by the drug.
Chlorpromazine affects many chemical, enzymatic and biologic 
functions, including inhibition of the enzymes that catalyze nucleic 
acid synthesis. This effect is felt chiefly in those tissues that turn 
over DNA rapidly; the hematopoietic cells (l75, 174).
Toxicoloov
Acute Toxicitv
According to Smith Kline and French Laboratory (334), in rats, 
the approximate 14-day follows:
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Chlorpromazine at 125 mg/kg i.m. produced death within 6 hours
in guinea pigs (229).
Chronic Toxicitv
In general, chronic toxicity studies have revealed no ill ef­
fects with chlorpromazine except for some depression of growth (due to 
lower food intake) at relatively high doses (334).
In guinea pigs, all organs and glands were unaffected by the 
drug, except that the male guinea pig thymus glands showed a decrease in 
weight (334).
Administration of 5 mg/kg of chlorpromazine per day subcutane- 
ously to pregnant rabbits caused no significant difference from control 
animals in size or viability of litters. Likewise, administration of 
10 mg/kg per day of chlorpromazine in food, to female rats, produced no 
ill effects on the mothers or litters; second generation studies showed 
no adverse effects (334).
Overdosaae
Overdose is a frequent cause of drug reactions, especially among 
the antianxiety drugs. It may be due to mistaken prescribing by physi­
cians or abuse of the drug by patients.
Several cases of intoxication due to overdose of chlorpromazine, 
taken either accidentally or intentionally, have been reported in .the
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literature (22, 152, 333, 111, 343, 97). Complete details are not avail­
able for all cases. The ingested amounts ranged from 250 to 9,800 mg 
(l31, 136, 22, 152, 333, 111, 343, 97), presumably taken as a single
dose, but it was so stated in only three instances.
It is evident that ingestion of about 10 to 50 mg/kg by humans
resulted in deep sleep, stupor and coma. When an amount over 64 mg/kg
was ingested, tremor and convulsion were also noted in most instances 
(22, 77, 349). This is in' accordance with the observations of Salzman 
and co-workers (309) on dogs and Essig and Carter (l05) on monkeys, re­
garding the effect of chlorpromazine on the central nervous system. Dif­
ferences in the clinical picture of intoxication following large over­
dosages are explained either by the partial removal of the ingested ma­
terial by gastric lavage or by the possibility that the amount actually 
was less than the alleged intake. The same reasons may account for the 
lack of coma and for the relatively short duration of the state of in­
toxication in spite of massive dosage such as seen in the case of Douglas 
and Bates (97).
Ingestion of 75 mg/kg of the drug by a 13-months-old child re­
sulted in death (l52). This case is the only published fatality attri­
buted to intoxication by chlorpromazine. Death occurred during hospital­
ization on the fourth day after ingestion. Autopsy showed generalized 
cerebral edema. The blood contained 0.1 mg per cent of free chlorproma­
zine.
Reports of detection and quantitation of chlorpromazine are 
scant in the reported cases. Douglas and Bates (97) and Beal (22) em­
phasize that gastric lavage is indicated even after a considerable lapse
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of time following ingestion since chlorpromazine diminishes the gastric 
motility, thus allowing the removal of some of the ingested material 
still remaining in the stomach.
When convulsions occur, the choice of an anticonvulsive drug is 
difficult since chlorpromazine may potentiate the action of many central 
nervous system depressants such as barbiturates and narcotics as well as 
anesthetics and alcohol (334). The makers of the drug are quite emphatic 
in their recommendations regarding the use of vasopressor drugs to combat 
hypotension. They state that non-epinephrine is the most suitable and 
that epinephrine should not be used since the chlorpromazine may reverse 
its action (334).
Haggerty (l52) suggests that exchange transfusion may be benefi­
cial in treating intoxication in children and that hemodialysis would be 
of no value.
Trace Elements
Associated with all vital processes and essential for all living 
cells are a few inorganic elements; most are classified in the periodic 
chart as being members of the transition series. They are: Mg, Mn, Fe,
Ca, Co, Cu, Zn, Mo. Though present in only micrograms per gram of body 
tissue, and therefore called trace elements, they have profound effects 
on all cellular functions (l25).
The term trace elements has been defined by many workers in this 
field, but it is generally agreed that any element that comprises less 
than 0.01 per cent of the organism is called a trace element (357). They 
are also known as micronutrients, oligonutrients, or minor elements as 
opposed to macro or bulk elements. The designation "trace," however.
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often refers to the extent of our technical and analytical ability of 
detecting that particular element in biological material rather than its 
relative concentration. Hence, our concept of a "trace" keeps changing 
as we keep improving our method of detection. For example, according to 
Vallee (S6l), zinc has lost its standing as a "trace" element because of 
its broad base of biological importance that has been recently discovered.
The biological role of trace metals was not elucidated until 
the early thirties. Prior to this, tools for their study were not avail­
able and even more important the advent of newer tools of biochemistry 
to isolate and characterize metalloenzymes were lacking. Today trace 
elements are recognized as vital parts of the biochemical makeup of the 
organism.
Essential trace elements are interdependent, and are generally 
associated with enzymes. Metal-dependent enzymes fall into two classes, 
(l) metalloenzymes which have a fixed amount of specific metallic ions 
firmly bonded to enzymes and whose metal/enzyme ratio is constant, (2) 
metal-activated enzymes where the metal is reversibly bonded to enzyme 
with a variable metal/protein ratio. Metals may substitute for each 
other and may also be removed by dialysis in the latter type of bonding.
A metal associated with the enzymes may play a variety of roles. 
One popular concept is that metals act as a bridge between substrate and 
the protein which activates the metal by withdrawing electrons from it, 
hence becoming positively charged and thus enabling it to withdraw elec­
trons from substrate. A chemical change is precipitated and hence the 
free energy of activation is lowered by the electronic alteration medi­
ated by the metal (l25).
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In other instances the metal plays an important role in the 
tertiary folding of the protein which may have to bring together two or 
three amino acid residues that are located far apart on a polypeptide 
chain, but which may become active when brought into the proximity of 
each other. It is believed that metals are bound to proteins mainly by 
the histidine residues in the protein (l25)
There are over 2,000 enzymes that regulate a vast number of 
chemical reactions within the cell. The metal coordinated to the enzyme, 
and in many cases with the substrate helps to regulate the speed of the 
reaction. Alteration of the metal environment alters the kinetics of the 
system.
According to Schroeder (322), four of the nine inorganic essen­
tial micronutrients cause deficiency disease and three cause disease of 
accumulation.
Schroeder (322) lists three types of trace metal deficiencies. 
These include simple deficiency such as iron and copper in man and Mo 
and Co in other mammals, and malabsorption or decreases in carriers of 
the blood such as zinc in Laennec's cirrhosis of the liver. Although 
overt toxicities of trace elements have been well established experimen­
tally as well as clinically, small chronic exposure over long periods of 
time is not well defined. There are also excesses of trace elements, 
certain diseases such as Wilson disease and copper accumulation (24,
357), and parkinsonism and high manganese concentration (67). Other 
types of excesses may be due to other large dietary intakes, increased 
absorption or decreased excretion resulting from other disorder such as 
in biliary obstruction or renal insufficiency (322).
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In spite of much speculation regarding essentiality of trace 
metals, several workers in this field (69, 273, 357) agree on the cri­
teria for essentiality. First, it is present in all healthy tissues of 
all living things. Second, its concentration from one animal to the next 
is fairly constant if compared to nonessentials; even the variability of 
human organs as found by Perry et al. (273) was more alike with respect 
to the absolute concentration of essential than of nonessential metals. 
Third, its withdrawal from the body induces in a reproducible fashion the 
same structural and physiological abnormalities regardless of the species 
studied. Fourth, its addition either prevents or reverses these abnor­
malities. Fifth, the abnormalities manifested by the deficiency state 
are always accompanied by pertinent, specific biochemical changes.
Sixth, these biochemical changes can be cured or prevented when the de­
ficiency is corrected. Hence, by these criteria a beneficial effect on 
growth or reproduction does not qualify an element as essential.
According to Underwood (357), the tremendous progress made dur­
ing the last 29 years in our understanding of metabolic movements of 
trace metals within the body and their mode of action within the tissues 
was greatly assisted and stimulated by concurrent developments in three 
major fields of study. The first of these involved the use of radioac­
tive isotopes of suitable half-life of virtually every element of bio­
logical interest. In the case of trace elements, absorption, retention, 
excretion, and kinetic studies were facilitated that were tedious, dif­
ficult, or impossible with the stable elements. The second significant 
development was in the field of enzymology, especially the discovery of 
a number of metalloproteins with enzymic activity and of trace element-
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catalyzed reactions in living tissues. These advances directed attention 
to the basic biochemical lesions associated with the diverse manifesta­
tions of trace element deficiencies and excesses in the body. Finally, 
the remarkable advances in analytical procedures such as emission spec­
troscopy, atomic absorption, and neutron activation, and more recently 
the laser and electron microprobes, which have enabled us to determine 
qualitatively and for some elements quantitatively, concentration at the 
cellular level. Table 2 shows selected enzymes and metal relationships.
Copper
It is estimated that the adult human body contains approximately 
100-150 mg of copper, most of which is concentrated in the liver and the 
central nervous system (357).
Newborn and very young animals are normally much richer in cop­
per per unit of body weight than adults of the same species. This is 
largely, but not entirely, a reflection of high liver copper storage at 
this stage (357).
Most of the copper present in the plasma is firmly bound to 
a-2-globulin called ceruloplasmin which according to Markowitz (235) was 
discovered first by Holmberg and Laurell. A small fraction, about 5 per 
cent is bound to albumin. The important metalloenzymes containing cop­
per are: ascorbic acid oxidase, uricase, cytochrome oxidase, and S-
aminolevulinic acid dehydrase (357). Red blood cells contain a copper 
protein called erythrocuprein (235). Cartwright (52) believes that cop­
per is involved in myelination of nervous tissue and the maintenance of 
normal skin pigmentation. Carnes et al» (49) and O'Dell et (267) 
postulate that copper-deficient animals have defects of vascular integrity
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ascribable to abnormalities in the biogenesis of elastin. Its action in 
erythropoiesis is probably due to the increased absorption of iron and 
its incorporation into protoporphyrin in the formation of heme (357).
The endocrine glands are examples of low copper tissues and the 
liver, heart, kidneys, hair, and brain, usually in that order, are ex­
amples of high copper concentration tissues (357). The copper concen­
trations in the liver, kidney, spleen, and lungs can be greatly increased 
by high copper intakes and those of the liver, kidney, spleen, and blood 
readily reduced under conditions of copper deficiency (357).
Hypercupremia occurs in most chronic and acute infections in 
man and in leukemia, Hodgkin's disease, various anemias, collagen disor­
ders, hemochromatosis, and myocardial infarction (361). According to 
Underwood (357) Hill reported elevated serum copper values in some cases 
of schizophrenia.
The average amount of copper ingested daily by an adult is about 
2.5-5.0 mg, 99 per cent of which appears in the stool, and the majority 
of that portion absorbed is excreted via the bile. About 70 mg appear 
in the urine per day (357).
Magnesium
Wacker (365) has stated that shifts in body magnesium result in 
deleterious effects and can produce significant clinical manifestations. 
The entire human adult body contains about 25 g. It is the fourth most 
abundant cation being exceeded only by calcium, sodium, and potassium. 
Hence, the term "trace" can hardly be applied in this situation. Magne­
sium is mainly intracellular with a concentration of 26 meq/d. Approxi­
mately half of the magnesium resides in the skeleton and exchange very
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slowly with the extracellular ions. The highest concentrations of magne­
sium are in the liver and muscle followed by the brain, kidney and red 
blood cells (365).
About one-third of the serum magnesium is bound to albumin and 
globulin and the remainder is in ionic form (365).
Magnesium is especially important in activating enzymes which 
transfer or hydrolyze phosphate groups, or in some cases split peptides 
as peptidases. Ribonuclease is also a magnesium-dependent enzyme (l25).
The average intake of magnesium for an adult is approximately 
300 mg although requirements may vary between infants and under certain 
conditions such as in pregnancy. Seventy-five per cent of the magnesium 
intake is absorbed (357).
Several diseases have been associated with altered magnesium 
metabolism. Miller (244) reported a hypomagnesemic tetany. Smith and 
Hammarsten (339) reported low plasma magnesium in delirium tremens which 
was followed by improvement upon administration of magnesium.
Vachon and Marchand (358) reported that in all tissues studied, 
with the exception of bone, magnesium concentration was found to be de­
creased one hour after morphine administration. Hypermagnesemia was ele­
vated within the first two hours of treatment, slowly returned to normal 
and became significantly lower 24 hours after morphine injection. Hills 
et al. (163) described adrenal insufficiency in which there was high 
level of plasma magnesium.
Manganese
The body of a normal 70 kg man is calculated to contain a total 
of sane 12-20 mg manganese (357). According to Underwood (357) Tauber
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and Krause reported that manganese is not specially concentrated in any 
organ or tissue so far examined. Even the pigmented portions of the eye, 
which are so rich in zinc and copper, are not exceptionally high in man­
ganese, although the retina appears to be somewhat richer in this metal 
than are most body tissues. The bones, liver, kidney, pancreas, and 
pituitary gland normally carry higher concentrations (l-3 p.p.m. Mn on 
the fresh basis) than do the other organs and the skeletal muscles 
(O.l - 0.2 p.p.m.) are among the lowest in manganese of the tissues of 
the body. In the liver and bones the levels can be raised or lowered by 
varying the manganese intake of the animal.
Cotzias (67) reported that ingested divalent manganese remains 
unchanged in the acid stomach, but as soon as it gets to the small intes­
tine it becomes oxidized since alkaline conditions are more favorable 
for oxidation. Absorbed manganese is transported via p-globulin plasma 
transmanganin, the trivalent form (67).
Manganese is poorly absorbed from the gut and is excreted very 
largely in the feces. Underwood (357) reports that the early studies of 
Greenberg and associates with Mn^^ indicated that only about 3-4 per 
cent of the orally administered dose was absorbed in the rats; it quickly 
appeared in the bile and a very high proportion was excreted in the feces.
Britton and Cotzias (38) and Borg and Cotzias (34) suggested 
that disorders due to manganese deficiency or excess may result from 
slow or rapid rates of turnover.
Quite a range of disturbances has been related to lack of die­
tary manganese in different species under varying conditions, but the 
cardinal manifestations, namely impaired growth, skeletal abnormalities.
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depressed or disturbed reproductive function, and ataxia of the newborn 
are similar in all species (357).
Everson and Shrader (l06) reported an impairment of glucose 
tolerance and utilization in young adult guinea pigs deficient in manga­
nese. Hurley (l84) and Hurley et (l85) studied maternal dietary de­
ficiency of manganese during pregnancy. They found irreversible congen­
ital ataxia in the offspring of rats, mice and guinea pigs. Supplement­
ing the diet with manganese during gestation completely prevented the de­
velopment of these abnormalities.
Liver arginase is the only enzyme other than alkaline phospha­
tase, that has been shown to be significantly reduced in activity in the 
tissues of manganese-deficient rats and rabbits (357).
Zinc
It is well established that zinc is an essential element for 
normal growth of most domestic animals (35). The metal is an integral 
part of the molecular structure of a variety of enzymes including alco­
hol dehydrogenase, glutamic dehydrogenase, lactic dehydrogenase, carbonic 
anhydrase, and alkaline phosphatase (357),
An average adult male contains about 2.2 g of zinc. Zinc occurs 
in all living cells in varying concentrations, with certain portions of 
the eye, the male sex glands and secretions, the hair, and the bones 
normally carrying significantly higher levels than other tissues and 
fluids. Most other organs contain on the average 20-30 mg/g wet weight.
Zinc is a constituent of the plasma or serum, of the erythro­
cytes and of the leucocytes. In the plasma it exists in both firmly 
bound and loosely bound fractions, associated with the serum albumin and
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globulins and most strongly bound to the latter (357).
The average daily intake of zinc is about 10-15 mg, 4 per cent
of which is excreted In the urine and the remainder is excreted in the
feces. Very little of absorbed zinc is excreted in the bile (357).
A dietary deficiency of zinc has been demonstrated in mice, 
rats, pigs, poultry and cattle, but not in sheep or man (357).
Deficiency of zinc produces subnormal growth, poor feeding ef­
ficiency, and testicular atrophy in dogs (300), rats (llS), pigs (356), 
and calves (243). Zinc deficient pigs develop parakeratotic skin le­
sions which are reversed by zinc feeding (356, 167). Zinc deficient 
chicks exhibit hyperkerotosis and poor feathering along with multiple 
skeletal defects (254, 267). Chick embryos hatched from zinc deficient 
eggs show a variety of bizarre congenital malformations (205).
Prasad and associates (290, 291, 292) demonstrated a convincing
etiologic role for zinc deficiency in certain Iranian and Egyptian males 
with iron deficiency anemia, hepatosplenomegaly, short stature and marked 
hypogonadism. Zinc feeding has been reported to have a salutary effect 
on alcoholic cirrhotics (361, 166).
Although it seems clear that zinc deficiency per se is followed 
by characteristic sequelae in animals and man, it is not clear that low 
tissue zinc concentration can be equated with zinc deficiency. In symp­
tomatic zinc deficient swine, skin, muscle, pancreas, intestine and blood 
may contain normal zinc content (357). However, Prasad et (293) 
have suggested that the tissue content of zinc controls physiologic proc­
esses through the formation of zinc-dependent enzymes.
Davies et al» (79) have demonstrated that plasma zinc concen-
63
tration is remarkably constant despite a continuous and relatively mass­
ive zinc turnover within the body. They demonstrated that glucose ad­
ministration is followed by prompt 5-10 per cent fall in plasma zinc 
concentration with recovery within 1-2 hours. Within this narrow limit, 
zinc concentration remained constant, with day-to-day variations being 
much less than for Cu, Ca or Mg.
CHAPTER III 
PURPOSE AND SCOPE
It is increasingly evident that toxic or adverse effects of 
drugs will continue to be a health problem, with increasing emphasis on 
long-term effects. Experience over the past decade has shown us that we 
can live with those reactions which are associated with valuable drugs 
and live without drugs of lesser value which may exact too great a price 
in side reactions. A number of drugs have fallen by the wayside for the 
latter reason, but overall, the list of safe and effective psychothera­
peutic agents has increased considerably in the period, with every ex­
pectation that it will continue to do so.
Chronic toxicity studies have shown that repeated doses of 
chlorpromazine produce several adverse effects, in which trace metal in­
volvement has been implicated, such as copper in the maintenance of nor­
mal pigmentation (52), zinc in hepatic dysfunction (l66) and high manga­
nese in parkinsonism.
Due to the importance of copper, magnesium, manganese and zinc 
in the function of certain metalloenzymes and other metabolic activities, 
as enumerated heretofore, it may be assumed that a concentration shift 
exhibited by any one of these metals provoke significant biochemical 




A survey of the literature concerning the action of chlorproma­
zine on the metalloenzymes reveals conflicting points of view. For in­
stance, various authors have reported that chlorpromazine increases, de­
creases, or has no effect on the alkaline phosphatase level of the vari­
ous tissues (379, 46, 177, 241, 211, 75).
These conflicting observations and others might be ascribed to 
different doses, timing, species, and above all in the methodology for 
the assessment of enzyme activity. In view of the lack of comparability 
among existing studies, a need for further research in several of the 
areas covered in this review is evident.
Therefore, it was felt necessary to study systematically the in­
fluence of chlorpromazine on trace metals and try to determine relation­
ships of observed trace metal effects to the changes in corresponding 
metalloenzymes reported in the literature.
This research project will determine the following: (a) which
of the organs, brain, heart, kidneys and liver exhibit the most promi­
nent changes in trace metal after chlorpromazine exposure, (b) the ef­
fect of varying periods of exposure to therapeutic levels of chlorproma­
zine on the trace metal status of the rat, (c) the practicality of trace 
metal methodology in monitoring the living system for adverse effects.
CHAPTER IV 
EQUIPMENT AND PROCEDURE
The ninety-six animals used in this study consisted of adult 
male King-Holtzman descent rats (250 to 350 g each with an average weight 
of 300 g) purchased from the Stanley-Gumbreck Company, Oklahoma City, 
Oklahoma. They were acclimated to the laboratory environment for 2 weeks 
and then examined for symptoms of illness after which time they were ran­
domized into six groups consisting of eight control and eight experimen­
tal rats per group. The first five groups of rats were placed in wire 
cages, eight per cage. The sixth group of rats were placed in individu­
al metabolic cages. Throughout the experiment all animals received water 
and purina rat pellets ad libitum. Each rat was weighed at the initia­
tion of the study, immediately prior to dosing, and again at sacrifice. 
The chronically exposed animals received a subcutaneous dose of 10 mg of 
chlorpromazine per kg of body weight, biweekly. The chlorpromazine was 
obtained from Smith Kline and French No. 2601A (Lot No. 116-771). The 
chlorpromazine injection solution was prepared by dissolving 10 mg of 
chlorpromazine per ml of 0.85 per cent saline, which was made up in de­
ionized water.




One group of animals, consisting of eight controls and eight 
expérimentais, was sacrificed at five day intervals during the 25 day 
study. The animals in the metabolic cages representing the last group.
The animals in the acute group received a single subcutaneous 
dose of chlorpromazine, 50 mg/kg of body weight. Sacrifice was effected 
at the third hour post injection.
The animals were sacrificed by decapitation utilizing a commer­
cial decapitator. Mixed trunk blood was collected in tubes. The serum 
was collected by centrifugation, then decanted into plastic screw top 
vials and frozen until the metal analyses could be performed.
Organs were obtained consistently in a similar fashion in order 
to avoid any changes due to surgical manipulation. The brain, heart, 
liver and kidneys were removed, blotted dry, cleaned of fat and connec­
tive tissue where necessary, and placed into preweighed vial and wet 
weights were determined. All containers were preacid washed and rinsed 
in deionized water. The samples were frozen until further sample prep­
aration could be performed.
Urine from control and chronic animals in metabolic cages was 
collected daily and pooled, to which was added 0.5 ml acetic acid as 
preservative.
Sample Preparations
The urine was aspirated directly into the flame using a premix 
burner for manganese. For copper, and zinc it was diluted 1 to 5. For 
magnesium a ten-fold dilution was needed.
One ml of serum was diluted to 5 ml with 4 ml of 10 per cent 
TCA and centrifuged, then decanted into clean tubes, which permitted
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direct aspiration of the samples into the burner of the atomic absorp­
tion unit.
The tissues (brain, heart, kidneys and liver) were subsequently 
thawed, placed into tared beakers and dried in an oven at 105*C for 16 
hours. Subsequently the tissues were placed in the electric furnace at 
500"C for 16 hours. The ash weight was determined after dessication 
overnight. After the weight of the ash was determined, 0.6 N HCl was 
added to each container in the following ratios of mg/ash to ml/acid: 
brain, 5:1, heart, 2:1, liver, 10:1 and kidneys, 5:1. The containers 
were then covered with parafilm and allowed to stand overnight. The acid 
and ash residue were transferred to a plastic screw top vial and stored 
until analysis.
All samples from the control and experimental animals were ana­
lyzed for manganese without further dilution. For copper, magnesium and 
zinc of brain, heart and kidneys, a ten-fold dilution was necessary. In
the liver a fifty-fold dilution was needed for these metals.
A set of standard solutions containing 10,000 ppm of copper, 
magnesium, manganese, and zinc, respectively (Fisher Scientific Company, 
Fairlawn, New Jersey) were serially diluted with 0.6 N HCl in order to 
obtain standards in the concentration ranges anticipated. These dilu­
tions were then used to prepare standard curves covering the indicated 
ranges: copper, 0.25 to 5.0 mg/ml; magnesium, 2.5 to 20 mg/ml; manga­
nese, 0.05 to 3.0 mg/ml; and zinc, 0.25 to 5.0 mg/ml. During analysis, 
appropriate standards were repeated with every eighth sample.
These analyses were accomplished with a Jarrell-Ash Atomic ab­
sorption Spectrophotometer Model 82-362 utilizing a 0.5 meter ebent mount
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monochrometer. Instrumental settings for each particular metal were 
optimized and a warm-up period was allowed for the whole system to sta­
bilize. The hollow cathode tube current for each metal was set accord­
ing to the manufacturers recommendations as follows: copper 5 ma, mag­
nesium 6 ma, manganese 5 ma, and zinc 6 ma. The corresponding resonance 
line for each metal was 3247A®, 2852A®, 2794A° and 2139A®, respectively.
Data were collected and analyzed statistically using the IBM 
1800 Computer of the Hospital Systems at University Hospital of the 
Oklahoma University Medical Center. For statistical purposes the data 
for the chronic study was treated as a 2 x 4 factorial arrangement (group 
factor at two levels - treated and control and time at four levels) with 
eight observations per cell. Primary emphasis in testing hypotheses was 
centered on the test for simple effects of time within group and group 
within time. For certain metals and organs, the heterogeneity of vari­
ance precluded the use of the usual analysis of variance technique.
These are indicated in the tables in the Appendix. Individual test for 
these were made using the Modified-t.
The data for the acute and metabolic studies were tested for 
difference between treated and control using the Student's t statistic. 
For all test of hypothesis the 5 per cent level of significance was used. 
Data are tabulated in the Appendix.
CHAPTER V 
OBSERVATIONS AND DISCUSSION
The observations on the acute, chronic, and control groups of 
rats are presented as a consideration of the response of copper, magne­
sium, manganese and zinc in the brain, heart, kidneys, liver, serum and 
urine. Secondarily, an attempt is made to correlate trace metal changes 
with selected metalloenzymes and metal activated enzymes. The compari­
sons of the treatment and control experimental parameters are shown in 
Tables 4 through 16 (Appendix), and these data are summarized in Table 3, 
which indicates the statistically significant increases and decreases by 
algebraic signs.
Trace metal values have been expressed in terms of concentra­
tion per ash weight.
Brain
Chlorpromazine appears to have caused only one significant dif­
ference between groups in rat brain weight parameters during the 25 days 
of this study. The ash weight was decreased at the end of 15 days, how­
ever in both groups, chronic and control there were significant decreases 
in wet weight with time. Only two significant alterations in metal con­
centration between groups occurred; magnesium was decreased at the end 
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exhibited the most prominent change in concentration of all tissue metal 
shifts observed. There was approximately an eleven-fold increase in 
zinc at this interval. The intra group variability was also signifi­
cant.
The absence of appreciable copper change in the brain appears 
to be in disagreement with the observations of Holbrook (168) which 
showed cerebellar cortex and caudate nuclei copper increases in the 
guinea pigs. This difference in observed copper alterations might be 
the result of species variation. On the other hand, our investigation 
appears to support observations by other investigators on cytochrome C 
oxidase of rat brain in which it was reported that no inhibitory effect 
was found (l26, 251).
The migration of magnesium out of the liver appears to be in ac­
cord with the observations that chlorpromazine inhibits adenosine tri­
phosphatase in liver and brain preparations (27, 81), and with those of 
Masurat et (237) which indicated that chlorpromazine either greatly 
activated or inhibited hexokinase activity. The biphasic action of 
chlorpromazine was said to be a function of the relative concentration of 
drug and Mg-ATP substrate.
The elevation of brain zinc in our investigation would tend to 
uphold the significant increase in brain alkaline phosphatase reported 
by Clark (63), however, it is not in accord with the findings by Chagovets 
et al. (55) which showed a 70-75 per cent decrease in lactic dehydrogen­
ase activity in brain tissue. Nevertheless, the observations discussed 
above appear to bolster the involvement of alkaline phosphatase in the 
rats response to chlorpromazine.
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Heart
The heart was the most sensitive to weight change parameters.
The heart wet weight was significantly decreased at the end of the 20 
day interval, the ash weight was increased at the 5 day interval and de­
creased at the end of 20 days. There were significant changes in ash 
weight among control and chronic groups with time.
Copper appeared to have been mobilized into the heart at the
10 day interval, however, there was a decreasing copper concentration 
with time in control and chronic rats. The acute rats exhibited a sig­
nificant decrease in heart copper concentration at 3 hour post injection.
Magnesium demonstrated a migration into the heart at the 5, 10,
and 25 day (metabolic group) intervals. However, there was a decrease 
in magnesium at the 20 day interval and in the acute rats.
The specimen was not sufficient to determine manganese.
Zinc appeared to migrate into the heart during the 5, 10, and 
20 day intervals, and migrate outward in the acute rats.
Kidnevs
The only kidney weight parameters observed to be altered was the 
wet weight at the end of the 20 day interval. Most of the metal changes 
were inward migrations. Copper was significantly increased at the end 
of the 20 day interval. There was an elevation in magnesium at the above 
interval, and in both the acute and the metabolic group (25 day interval).
Manganese demonstrated a consistently decreasing concentration 
in the kidneys with time in control and chronic groups. There was an in­
crease in manganese concentration of the kidneys of the acute rats.
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Liver
The liver of the acute rats demonstrated the only change in
liver weight parameters. The ash weight showed a significant increase
in this group. Copper was elevated in the metabolic group (25 day in­
terval), and depressed in the acute group.
Magnesium was significantly depressed in the acute group. The 
chronic rats showed a significant decrease in manganese at the end of 
the 5 day interval. There was significant intra variation in manganese 
concentration in the liver of chronic rats.
Several different patterns of changes appear to have occurred
in the zinc concentration of the liver. There was an intra as well as
an inter group variability, which was very significant at the 10 and 20 
day intervals.
The shift in manganese concentration of the liver of acute rats 
and the absence of alterations in manganese concentration in the liver 
of the chronic rats appear to be in accord with the reported observations 
by Klinger et (206) which did not show any decrease in the activity 
of liver arginase in the in vivo experiment after 89 to 93 days of chlor­
promazine treatment.
Serum
There was an intra as well as inter group variability in metal 
concentration in the serum of the chronic rats which was highly signifi­
cant. Copper appears to have been mobilized into the serum at the end 
of the 10 day interval. Our findings are not in complete accord with 
those of Azima (l6) in patients which showed a gradual rise in plasma 
copper concentration, however, the alterations were in the same direc­
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tion. On the other hand, Nunez (265) reported a decrease in plasma cop­
per of nearly all of the 50 patients examined, but an increase in plasma 
copper of manic depressive patients.
Both magnesium and zinc serum concentrations have shown a con­
sistently decreasing concentration with time in the chronic rats over 
the 20 days examined.
Urine
Significant metal alterations in the urinary excretion did not 
occur except for a decrease in magnesium at the end of the 5 day inter­
val. However, no consistent pattern of urinary magnesium concentration 
was observed due to its erratic behavior in both controls and experimen­
tal rats. This inconsistency may possibly be explained by the changing 
of the food of the metabolic rats on three different occasions.
Inasmuch as all of these metal-enzyme correlations involve dif­
ferent strains of animals, species, doses, routes of administration, 
time intervals of sampling, and other variables, no definitive statements 
can be formulated, only suggestions that need to be subjected to further 
studies. Due to the lack of a consistent pattern of metal alterations 
between control and chronic treated rats, except for an almost consistent 
trend of zinc increase in the heart, the author believes that this study 
should be duplicated and the exposure period extended.
CHAPTER VI 
SUMMARY AND CONCLUSIONS
In this series of experiments ninety-six male Holtzman-King de­
scent rats were used to assess the effects of chlorpromazine upon trace 
metal shifts quantitatively and the time course of the various elements 
of response was defined. The animals were randomly divided into six con­
trol groups of eight; a group of eight which received a single subcuta­
neous (s.c.) acute dose of 50 mg of chlorpromazine per kg of body weight; 
and five chronic groups of eight; which received 10 mg/kg of body weight 
of chlorpromazine (s.c.) biweekly. One group of control and chronic 
rats was sacrificed at every five-day interval for a period of twenty- 
five days. The sixth group of controls and chronic treated animals were 
placed in metabolic cages.
Chlorpromazine effects were determined by alterations in the 
concentration of copper, magnesium, manganese and zinc in the brain, 
heart, kidneys, liver, and serum of all groups and the urine of the last 
(25 days) group.
In the 2,300 determinations made by atomic absorption spectro­
scopy on the various samples, differences were sought between control 




1. Analysis of data from this study showed that generally 
chlorpromazine had inconsistent effects on organ weight 
parameters. The brain appears to increase in wet weight 
with time, while the heart increased in ash weight over the 
20-day period, and also between chronic and control groups 
at the 5-day interval. Other organs showed similar incon­
sistencies.
2. As might be expected, each organ presented an individual 
pattern of trace metal changes due to chlorpromazine admin­
istration. The observed metal alterations were inconsist­
ent. No definite trend was detected.
3. Zinc demonstrated the most significant change of the metals 
examined. The brain zinc concentration was elevated three­
fold at the 20-day interval.
4. Manganese was the least responsive to chlorpromazine admin­
istration. Its only significant shifts were a mobilization 
into the kidneys of the acute group, and a decrease in liver 
manganese concentration at the 5-day interval, and an intra 
variation in the chronic rats.
5. Copper exhibited significant inter and intra variation in 
the heart, and significant differences in the serum after 
10 days, and in the liver of both acute and 25-day chronic 
rats.
6. Magnesium demonstrated the most variable response observed. 
There were either exceedingly large intra or inter varia­
tion or both in most of the tissues examined.
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7. The significant increase in serum copper after 10 days, and
the decrease in serum zinc concentration with time during
the 20 days examined, along with the studies by Azima (l6) 
and Nunez (265), tend to indicate that trace metal method­
ology, in serum, might be useful for monitoring adverse ef­
fects due to chlorpromazine administration.
8. In general, evidence from other studies, in conjunction
with the present investigation, suggests that chlorproma­
zine administration induces alterations in various enzymes 
and associated metals, including alkaline phosphatase, cyto­
chrome oxidase, adenosine triphosphatase and liver arginase.
These results do not rule out other factors, but 
it is felt that there is sufficient evidence to indicate 
that the enzymes previously listed and their related metals 
are involved in the biochemical response of the rat and 
other organisms to chlorpromazine administration. But be­
cause of the many variables, species of animals, dosages 
and route of chlorpromazine administration, only suggestions 
can be made at this time. Further studies, utilizing more 
frequent sampling and additional animal species, in conjunc­
tion with human studies, need to be done before any defini­
tive conclusions can be formulated.
9. The following metal alteration with associated metalloen- 
zyme or metal activated enzyme should be studied further on 
an hourly basis, followed by daily sampling, then weekly 
sampling for chronic response to chlorpromazine administra-
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tion in order to provide a better understanding of their
involvement:
(a) significant increases of zinc in brain tissue, and al­
kaline phosphatase activity.
(b) significant increases of copper in serum, kidney and 
liver tissue along with cytochrome oxidase.
(c) the elevation and/or depression of magnesium in heart, 
brain, kidney, liver and serum in conduction with 
adenosine triphosphate and hexokinase activity.
These studies should be done to provide information for evalu­
ating the response of trace metals and their relationship to enzyme 
changes as an additional toxicological tool for assessing adverse ef­
fects.
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MEAN WET WEIGHT (grams) AND VARIATION OF INDICATED TISSUE 
FOR ACUTE AND METABOLIC RATS
Tissues Control Acute Control 25-Day
grams grams t-value grams grams t-value
X 1.685 1.731 0.724 2.094 1.601 2.122
Brain S2 0.0132 0.0151 0.3204 0.0038
n 7 7 6 6
X 1.048 0.963 1.211 0.952 0.927 0.366
Heart S2 0.0190 0.0154 0.0159 0.0142
n 7 7 6 6
X 2.353 2.223 0.903 2.502 2.415 0.483
Kidneys S2 0.0049 0.0543 0.0986 0.0949
n 7 7 6 6
X 9.398 9.188 1.059 11.833 11.593 0.252
Liver S2 1.8660 1.1215 1.7956 3.6443
n 7 7 6 6
Ill
TABLE 5
MEAN ASH WEIGHT (milligram) AND VARIATION OF INDICATED TISSUE 
FOR ACUTE AND METABOLIC RATS
Tissues Control Acute Control 25-Day
mg mg t-value mg mg t-value
X 26.543 28.700 1.541 26.500 23.933 1.769
Brain S2 6.584 7.1396 4.7524 7.8736
n 7 7 6 6
X 11.643 12.543 1.230 9.717 9.433 0.419
Heart S2 2.8123 0.937 1.3619 1.3877
n 7 7 6 6
X 28.916 29.483 0.33 31.633 30.050 0.702
Kidneys S2 9.7406 7.5790 14.9846 15.5078
n 7 7 6 6
X 107.857 147.142 2.840® 201.550 185.866 0.797
Liver S2 308.8455 1029.8323 1306.3887 1011.5582
n 7 7 6 6
^Significant at the 0.05 level.
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TABLE 6
MEAN œNCENTRATION (iig/mg) AND VARIATION OF
COPPER IN ASH OF INDICATED TISSUE
FOR ACUTE AND METABOLIC RATS
Tissues Control Acute Control 25-Day
pg/mg pg/mg t-value H-g/mg Hg/mg t-value
X 0.181 0.178 0.261 0.212 0.210 0.072
Brain Ŝ 0.0096 0.0003 0.0038 0.090
n 7 7 6 6
X 0.378 0.276 5.754® 0.450 0.491 1.335
Heart S2 0.0067 0.0015 0.0053 0.0003
n 7 7 6 6
X 0.628 0.591 0.685 1.370 1.792 1.017
Kidneys Ŝ 0.0049 0.0132 0.7090 0.3204
n 7 7 6 6
X 0.241 0.200 2.419® 0.121 0.168 2.810
Liver S'-̂ 0.0014 0.0015 0.0004 0,0003
n 7 7 6 6
X 1.490 1.334 1.645 1.995 1.507 1.512
Serum S^ 0.0520 0.0100 0.5700 0.0529
n 7 7 6 6
Poolëd X 0.391 0.330 1.721
Urine s% 0.00313 0.00302n 5 5
Significant at the 0.05 level.
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TABLE 7
MEAN CONCENTRATION (fig/mg) AND VARIATION OF
MAGNESIUM IN ASH OF INDICATED TISSUE
FOR ACUTE AND METABOLIC RATS
Tissues Control Acute Control 25-Day
ixg/mg W/mg t-value p-g/mg Hg/mg t-value
X 11.214 10.918 0.780 11.983 12.048 0.130
Brain Ŝ 0.5625 0.4529 0.7191 0.7850
n 7 7 6 6
X 18.683 16.582 2.580® 23.610 26.532 2.520®
Heart S^ 1.7240 2.9173 3.2616 4.7917
n 7 7 6 6
X 14.969 16.303 2.883® 14.412 17.125 2.948®
Kidneys S2 0.7396 0.5417 3.7095 1.3689
n 7 7 6 6
X 13.131 11.120 2.580® 11.301 13.191 2.120
Liver S^ 0.3721 3.8416 1.1664 3.5721
n 7 7 6 6
X 21.695 22.244 0.567 23.736 24.807 0.848
Serum Ŝ 2.3562 4.1943 3.5797 5.9585













Significant at the 0.05 level.
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TABLE 8
MEAN œNCENTRATION (pg/mg) AND VARIATION OF
MANGANESE IN ASH OF INDICATED TISSUE
FOR ACUTE AND METABOLIC RATS
Tissues Control Acute Control 25-Day



































































Sample not sufficient. 




MEAN œNCENTRATION (p.g/mg) AND VARIATION OF
ZINC IN ASH OF INDICATED TISSUE





t-valueJig/mg |j,g/mg Jig/mg Jig/mg
X, 0.745 0.730 0.503 0.810 0.814 0.087
Brain S2 0.0026 0.0036 0.00028 0.00774
n 7 7 6 6
X 4.259 3.919 2.548® 4.882 5.151 1.005
Heart S2 0.0930 0.0306 0.3795 0.0467
n 7 7 6 6
X 1.641 1.631 0.534 1.830 2.150 2.110
Kidneys S2 0.0112 0.0058 0.0515 0.0864
n 7 7 6 6
X 2.145 1.865 2.038 1.644 1.861 1.552
Liver S2 0.0132 0.1183 0.0918 0.0250
n 7 7 6 6
X 1.219 1.317 0.908 1.464 1.426 0.338
Serum S2 0.0520 0.0282 0.0225 0.0548
n 7 7 6 6
X, 1.8696 1.9082 0.11056
Urine S2 0.27961 0.3297
n 5 5
Significant at the 0.05 level.
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TABLE 10
A TYPICAL EXAMPLE OF THE STATISTICAL ANALYSIS 
FOR CHRONIC RATS
Copper Content of Heart Tissue 


















Time 0.108031854 0.36010618 1.591
Within





Control 0.844976 3 0.281658 12.44®
Chronic 0.126899 3 0.422997 18.69®
Days SS
Group within Time 
DF MS F
5 0.257556 1 0.257556 1.13
10 0.975156 1 0.975156 4.30®
15 0.187056 1 0.187056 0.82
20 0.175564 1 0.175564 0.07
Significant at the 0.05 level.
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TABLE 11
MEAN WET WEIGHT (grams) IN INDICATED 
TISSUES AND TREATMENT GROUPS 
FOR CHRONIC RATS













































^Significant difference with time. 
^Significant difference between groups.
118
TABLE 12
MEAN ASH WEIGHT (milligrams) IN INDICATED 
TISSUES AND TREATMENT GROUPS 
FOR CHRONIC RATS















































^Significant difference between groups. 
^Significant difference with time.
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TABLE 13
MEAN COPPER CONCENTRATION (ng/mg ASH) IN INDICATED 
TISSUES AND TREATMENT GROUPS 
FOR CHRONIC RATS
























































Significant difference with time.
Significant difference between groups.
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TABLE 14
MEAN MAGNESIUM CONCENTRATION (iig/mg ASH) IN INDICATED 
TISSUES AND TREATMENT GROUPS 
FOR CHRONIC RATS
























































^Significant difference between groups.
^Significant difference with time.
^Heterogeneity prevented the use of analysis of variance in this
analysis. Individual differences by modified t-test.
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TABLE 15
MEAN MANGANESE CONCENTRATION (iig/mg ASH) IN INDICATED 
TISSUES AND TREATMENT GROUPS 
FOR CHRONIC RATS















































'̂ Significant difference with time. 




MEAN ZINC CONCENTRATION ([ig/mg ASH) IN INDICATED 
TISSUES AND TREATMENT GROUPS 
FOR CHRONIC RATS
























































^Heterogeneity prevented the use of analysis of variance in this 
analysis. Individual differences by modified t-test.
^Indicates significant difference between groups.
^Indicates significant difference with time.
